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ABSTRACT 
Tumbleson, Danika M. M.S., Purdue University, December 2014. Treatment and Genetic 
Analysis of Craniofacial Deficits Associated With Down Syndrome.  Major Professor: 
Randall J. Roper. 
 
Down syndrome (DS) is caused by trisomy of human chromosome 21 (Hsa21) 
and occurs in ~1 of every 700 live births. Individuals with DS present craniofacial 
abnormalities, specifically an undersized, dysmorphic mandible which may lead to 
difficulty with eating, breathing, and speech. Using the Ts65Dn DS mouse model, which 
mirrors these phenotypes and contains three copies of ~50% Hsa21 homologues, our lab 
has traced the mandibular deficit to a neural crest cell (NCC) deficiency in the first 
pharyngeal arch (PA1 or mandibular precursor) at embryonic day 9.5 (E9.5).  At E9.5, 
the PA1 is reduced in size and contains fewer cells due to fewer NCC populating the PA1 
from the neural tube (NT) as well as reduced cellular proliferation in the PA1. We 
hypothesize that both the deficits in NCC migration and proliferation may cause the 
reduction in size of the PA1.  To identify potential genetic mechanisms responsible for 
trisomic PA1 deficits, we generated RNA-sequence (RNA-seq) data from euploid and 
trisomic E9.25 NT and E9.5 PA1 (time points occurring before and after observed 
deficits) using a next-generation sequencing platform. Analysis of RNA-seq data 
revealed differential trisomic expression of 53 genes from E9.25 NT and 364 genes from 
E9.5 PA1, five of which are present in three copies in Ts65Dn. We also further analyzed 
xi 
 
the data to find that fewer alternative splicing events occur in trisomic tissues compared 
to euploid tissues and in PA1 tissue compared to NT tissue. In a subsequent study, to test 
gene-specific treatments to rescue PA1 deficits, we targeted Dyrk1A, an overexpressed 
DS candidate gene implicated in many DS phenotypes and predicted to cause the NCC 
and PA1 deficiencies. We hypothesize that treatment of pregnant Ts65Dn mothers with 
Epigallocatechin gallate (EGCG), a known Dyrk1A inhibitor, will correct NCC deficits 
and rescue the undersized PA1 in trisomic E9.5 embryos. To test our hypothesis, we 
treated pregnant Ts65Dn mothers with EGCG from either gestational day 7 (G7) to G8 or 
G0 to G9.5. Our study found an increase in PA1 volume and NCC number in trisomic 
E9.5 embryos after treatment on G7 and G8, but observed no significant improvements in 
NCC deficits following G0-G9.5 treatment.  We also observed a developmental delay of 
embryos from trisomic mothers treated with EGCG from G0-G9.5. Together, these data 
show that timing and sufficient dosage of EGCG treatment is most effective during the 
developmental window the few days before NCC deficits arise, during G7 and G8, and 
may be ineffective or harmful when administered at earlier developmental time points. 
Together, the findings of both studies offer a better understanding of potential 
mechanisms altered by trisomy as well as preclinical evidence for EGCG as a potential 
prenatal therapy for craniofacial disorders linked to DS. 
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CHAPTER 1. INTRODUCTION 
 
1.1  Overview of Down Syndrome 
  Down syndrome (DS) occurs in ~1/700 live births (Parker et al. 2010) and is 
caused by trisomy of human chromosome 21 (Hsa21).  DS is the most common live born 
chromosomal aneuploidy and the most common genetic cause of intellectual disability 
(ID). In addition to this phenotype, individuals display alterations in many tissues and 
organ systems including varied facial features, congenital heart defects, skeletal 
deficiencies, hypotonia, gastrointestinal disease, and shortened stature. However, these 
phenotypes present with varying penetrance and severity.  The mechanism by which 
Trisomy 21 causes variability in the expression of phenotypes is not fully understood.  
However, current research has made progress in identifying genotype-phenotype 
correlations in DS.  
 Down syndrome was first described in 1846 by Édouard Onésimus Séguin, who 
later became the first president of the American Association for Mental Deficiency.  He 
was a founder of methods for educating those in France and the United States to those 
considered to display mental retardation. Although he was the first to describe the 
disorder, evidence of DS exists in the archaeological record as early as 500 A.D. in 
Mexican terra-cotta (Martinez-Frias 2005) and in many European paintings from 1500 
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A.D. onward (Berg and Korossy 2001).  In 1866, John Langdon Down, for whom DS is 
named, described the group of phenotypes that were later named after him.  He correctly 
described several of the characteristic facial features including a ‘face that is flat and 
broad’, has a ‘very narrow palpebral fissure’, and a tongue that ‘is long, thick, and much 
roughened’ (Down 1866; Neri and Opitz 2009).  It was not until almost 100 years later, 
following the development of karyotyping technology, that Jerome Lejeune and Patricia 
Jacobs identified an extra copy of chromosome 21 as the genetic cause of DS (Lejeune et 
al. 1959a; Lejeune et al. 1959b). Since the genetic cause of DS was identified, great 
progress has been made in DS research including a better characterization of phenotypes, 
creation of mouse models of trisomy, and the sequencing of chromosome 21 in 2000 
(Hattori et al. 2000; Megarbane et al. 2009).  This progress, along with improvements in 
medical care and increased socialization over the last several decades, have led to an 
increased life expectancy of over 50 years of age for individuals with DS (Coppus 2013). 
 
1.2  Genetic Basis and Incidence of Trisomy 21 
 Trisomy 21 most commonly develops as a result of non-disjunction of a whole or 
part of Hsa21 during Meiosis I or II in the developing gametes. Trisomy occurs most 
often when chromosomes do not separate properly and remain together in the same 
oocyte or sperm (Figure 1.1).  In 88% of cases, the gamete carrying the extra 
chromosome is transmitted from the oocyte, while only 8% of cases originate from the 
sperm, and 4% originate mitotically (Antonarakis 1991; Muller et al. 2000).  Although 
more rare, Trisomy 21 can also be caused by translocation of Hsa21 or display as a 
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mosaicism where the genome consists of a mix of trisosmic and euploid cells. Trisomy 
21 occurs randomly and its incidence is not heritable in most cases.  Any heritability in 
Trisomy 21 usually occurs when the trisomy is caused by a translocation of Hsa21. 
 The only factor correlated with an increased incidence of DS is advanced 
maternal age (Allen et al. 2009).  No correlation has been made between Trisomy 21 
pregnancies within any particular ethnicity, socio-economic status, or with smoking or 
alcohol consumption habits during pregnancy.  However, more babies with DS are born 
in certain countries and within certain ethnic groups because of discrepancies in choice to 
terminate the fetus following a DS diagnosis (Guedj and Bianchi 2013).  It is 
hypothesized that higher rates of DS occur in mothers over 35 years of age because the 
cellular machinery in the egg breaks down as the age of the egg increases. Although 
incidence of DS increases with maternal age, the overall birth rate of babies with DS is 
higher in younger women, since more babies are born to women under 35 (Huether et al. 
1998; Driscoll and Gross 2009). 
 
1.3  Prenatal Diagnosis of Down Syndrome 
 Prenatal testing is commonly practiced with the purpose of detecting fetal 
aneuploidies, specifically trisomies 13, 18, 21 and aneuploidies related to the X and Y 
chromosome (Gorzelnik et al. 2013; Lim et al. 2013).  The majority of aneuploidies 
result in natural fetal termination, usually within the first trimester. However, Trisomy 21 
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displays the highest survival rate, affecting 1 in 700 live births (Parker et al. 2010).  For 
this reason, prenatal testing is most utilized in detection of Trisomy 21 (Lim et al. 2013). 
 Currently, several procedures exist to detect Trisomy 21 and include both prenatal 
screening and prenatal testing procedures.  Prenatal screening tests such as the nuchal 
translucency test and non-invasive prenatal testing (NIPT) are used to provide initial risk 
assessment of fetal chromosomal abnormalities. They are easy to perform, present 
negligible risk to the fetus or mother, and are non-invasive (Lim et al. 2013).  Although 
these screening tests do not provide a definitive diagnosis, they are powerful tools in 
helping to make a decision whether to undergo further invasive testing to obtain a 
diagnosis.  To establish a Trisomy 21 diagnosis, prenatal diagnostic testing procedures 
such as chorionic villus sampling (CVS) or amniocentesis are routinely used. These tests, 
however, are invasive and present a small risk to the fetus.  When making decisions about 
prenatal screening or diagnostic testing, it is common for patients to be referred for 
genetic counseling to facilitate the decision making process. 
 
1.3.1  Nuchal Translucency Test 
 Prenatal screening tests are usually performed in the first trimester.   Nuchal 
translucency testing in particular is performed at 11-14 weeks during pregnancy. This test 
uses ultrasound to assess the quantity of fluid in the tissue at the nape of the fetus’s neck. 
Fetuses with DS tend to have a greater amount of fluid around the neck.  This test is often 
combined with analysis of maternal age and maternal plasma to detect pregnancy 
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associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-
hCG) to provide a more accurate risk estimation for chromosomal aneuploidy (Malone et 
al. 2005).  Although these prenatal screening tests cannot confirm a DS diagnosis, they 
are valuable tools as they identify more than 90% of DS cases with a 5% false positive 
rate (Lim et al. 2013). 
 
1.3.2  Non-invasive Prenatal Testing 
 As a more potent screening test for DS, NIPT is rapidly evolving as a prenatal 
diagnostic tool for DS with the advent of next-generation sequencing technologies.  It 
requires only a blood sample from the mother and can be performed easily, at low cost, 
and at negligible risk to the fetus (Daley et al. 2014).  The test measures low levels of 
cell-free fetal DNA (cffDNA) circulating freely in the maternal bloodstream. DNA in the 
blood is sequenced and ratios of DNA from Hsa21 analyzed. A mother carrying a fetus 
with DS will show higher levels of DNA from Hsa21 relative to that of other 
chromosomes.  Although this test provides advantages over invasive procedures in cost 
and fetal risk, it is limited by the amount of cffDNA detectable in maternal blood, which 
is usually only 3-5%. However, NIPT has been reported to detect cases of DS as early as 
6-10 weeks during pregnancy and has a high detection rate for DS (99-100%) with a low 
false positive rate (<1%) (Bianchi et al. 2012; Norton et al. 2012; Palomaki et al. 2012). 
This test is becoming more widely used and with continued development may replace 
invasive tests such as amniocentesis and CVS in the future. 
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1.3.3  Amniocentesis and Chorionic Villus Sampling 
 Once prenatal screening tests have indicated the fetus is at risk for a chromosomal 
aneuploidy, invasive testing using amniocentesis or chorionic villus sampling (CVS) can 
be performed to provide a definitive diagnosis. Amniocentesis is performed by taking a 
small amount of amniotic fluid from the placenta through a fine needle inserted through 
the abdomen. CVS is performed by taking a small sample of cells from the amniotic sac 
where it attaches to the wall of the uterus. These tests carry several disadvantages; 
however, amniocentesis and CVS sampling both carry significant risks of damaging a 
healthy fetus. They have a 1% miscarriage rate, are costly, and require expert technicians 
(Lim et al. 2013). Despite these risks, amniocentesis and CVS are estimated to be 98-
99% accurate in the diagnosis of DS (ACOG Practice Bulletin No. 88, 2007; Wilson et 
al. 2013). These tests are most often used to confirm a DS diagnosis after NIPT and 
nuchal translucency tests have indicated the fetus has a high risk of carrying DS. 
 
1.3.4  Current Trends in Prenatal Testing for Down Syndrome 
 The importance of prenatal screening and testing procedures in DS is growing as 
it provides the basis of decisions regarding future fetal and prenatal care.  Several studies 
have noted both positive and negative effects of the increased commonality of prenatal 
diagnostics in DS.  With the increase in average maternal age observed in the last 10-15 
years worldwide, there has also been an increase in the prevalence of DS cases, which 
includes still births, live births and terminated affected pregnancies (Loane et al. 2013).  
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However, with increased availability of prenatal screening and testing, the number of DS 
live births has remained largely unchanged as there is a growing trend in choice to 
terminate an affected pregnancy following a DS diagnosis. This trend holds true in many 
European countries where prenatal screening and testing is readily available, but does not 
hold true in all countries worldwide; the percentage of DS live births per DS case vary 
widely between countries depending on availability of testing, government policy, 
ethnicity and attitudes towards fetal termination (Morris and Alberman 2009; Cocchi et 
al. 2010; van Gameren-Oosterom et al. 2012; Loane et al. 2013).  Although there has 
been an overall growing trend towards increased termination of DS pregnancies, there are 
still many mothers who opt to carry a DS pregnancy to term and raise a child with DS.  
Studies of mothers who chose to keep their child with DS and had a DS prenatal 
diagnosis indicate that the diagnosis was beneficial for them during their pregnancy. 
Mothers who chose to keep their child with DS who did not have a prenatal diagnosis but 
received one at their child’s birth also indicated that an early diagnosis would have been 
beneficial during their pregnancy (Ralston et al. 2001).  
 In the future with continued research, early diagnosis of a DS pregnancy may 
offer an opportunity for prenatal treatment of an affected fetus during a small window of 
development where phenotypes associated with DS can be preventatively improved.  
Many studies have already found that such prenatal treatment can positively impact brain 
development and improve postnatal neurocognition and behavior in DS mouse models 
(Guedj and Bianchi 2013). The importance of prenatal diagnosis will continue to increase 
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as further study and development of prenatal treatments may provide additional options 
for those carrying a fetus with DS. 
 
1.4  Gene Dosage Imbalance in Trisomy 21 
 The mechanism by which gene dosage imbalance in Trisomy 21 causes 
characteristic DS phenotypes is not well understood. However, the presence of an extra 
copy of Hsa21 is known to disrupt developmental gene pathways in DS.  In particular, 
the increased gene copy number of the triplicated ~350 protein-coding Hsa21 genes 
causes dysregulation of both trisomic and non-trisomic genes in related downstream 
pathways (Kahlem et al. 2004; Chou et al. 2008; Billingsley et al. 2013; Letourneau et al. 
2014) and often in genes involved in regulating developmental processes. Current 
research has focused on identifying genotype-phenotype correlations. This has proved 
difficult as individuals carrying complete Trisomy 21 display many phenotypes with 
widely varying severity. However, progress has been made in identifying genotype-
phenotype correlations.  These approaches have included mapping of human partial 
Trisomy 21 cases (Korbel et al. 2009), construction of partial trisomy mouse models, and 
gene expression analysis studies in cells and tissues of individuals with DS and in mouse 
models of DS (Lyle et al. 2009). 
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1.5  Down Syndrome Phenotype 
 Individuals with DS may display over 80 clinical phenotypes that vary widely in 
severity. Some features are common to all individuals with DS to varying degrees 
including characteristic facial dysmorphology, intellectual disability, a small, 
hypocellular brain, and early onset Alzheimer’s disease (Roper & Reeves 2006).  There is 
also an increased risk for many other conditions including congenital heart defects (40-
50% of cases), incidence of childhood leukemia, and Hirschsprung disease. Many 
individuals also display skeletal deficiencies and hypotonia, or low muscle tone. At birth, 
hypotonia is often used as an indicator of DS if the condition was undetected during 
pregnancy. Although many of the phenotypes associated with DS present challenges, 
higher rates in the suppression of solid tumor growth is observed and the incidence rate 
of many cancers is significantly reduced in the DS population (Sussan et al. 2008; Baek 
et al. 2009) 
1.5.1  Craniofacial Phenotype 
 All individuals with DS display some form of characteristic facial dysmorphology 
(Roper and Reeves, 2006).  This characteristic dysmorphology of the face results mainly 
from malformation of the underlying craniofacial skeleton (Richtsmeier et al. 2002). 
Compared to humans with a normal chromosome compliment, DS craniofacial structure 
is characterized by an overall reduction in head size, flattened occiput, a small midface 
and reduced facial height, flattened nasal bridge, mediolaterally reduced orbital region, 
reduced bizygomatic breadth, small maxilla and mandible, brachycephaly, and dental 
anomalies (Richtsmeier et al. 2000; Richtsmeier et al. 2002; Shott 2006; Starbuck et al. 
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2013). These alterations in craniofacial structures contribute to differences in soft tissue 
structure including upslanting palpebral fissures and inner epicanthic folds (Epstein 
2001).  Although these phenotypes are displayed in all individuals with DS, there is a 
great deal of individual variability in the severity of expression of these phenotypes. 
 Altered structure of the craniofacial skeleton in DS, particularly the small jaw and 
oral cavity, impacts the structure or function of many orofacial structures including the 
airways and tongue, causing impaired eating, breathing, and speech (Hennequin et al. 
1999; Shott 2006; Faulks et al. 2008; Billingsley et al. 2013). In particular, individuals 
with DS often display tongue hyper portrusion as a result of the reduced size of the 
mandible causing a relative macroglossia. (Hennequin et al. 1999; Guimaraes et al. 
2008). The relative macroglossia and reduced oral cavity contribute to complications with 
the development of suckling, mastication, swallowing and speech  (Hennequin et al. 
1999).  It is reported that 57-68% of newborns and children with DS have feeding 
problems (Spender et al. 1996; Spahis and Wilson 1999) which may persist through 
adulthood with as many as 25% of adults with DS reporting eating difficulties 
(Hennequin et al. 2000).  Orofacial alterations can also lead to a constricted airway which 
can cause subglottic stenosis and obstructive sleep apnea  (Shott 2006).  This can result in 
fatigue during the day which has been reported to cause additional challenges in learning 
ability. Speech development is also hindered in part by orofacial alterations, and 
additionally by learning disabilities and hearing loss in some cases (Kent and Vorperian 
2013).  Together, these alterations can prevent individuals with DS from reaching their 
full developmental potential and reduce their quality of life. 
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1.6  Mouse Models of Down Syndrome 
 Animal models have been of great use in understanding growth and early 
development in DS. Because mammals share conserved gene homology, research with 
animals has led to a greater understanding of genotype-phenotype correlations in humans. 
Knowledge of these correlations has aided in the discovery of underlying causes of many 
genetic disorders and various diseases and have led to proposed treatments. Mouse 
models in particular are used to model many human conditions because of conserved 
gene homology, low cost of maintenance, and high fecundity, allowing developmental 
progression to be studied at a quickened rate (Frick et al. 2013). 
  The trisomic genes found on Hsa21 are also found grouped on three chromosomes 
in the mouse. In particular, the long arm of Hsa21 is 33.7 Mb in size and contains 
approximately 444 genes with homologues on mouse chromosomes 10, 16, and 17 
(Sturgeon and Gardiner 2011).  Of the 444 Hsa21 genes, about two-thirds have a gene 
homologue on Mmu16, while the remaining third can be found on Mmu10 and Mmu 17. 
Several mouse models have been created that provide partial trisomies modeling DS. The 
Ts65Dn mouse model, containing segmental trisomy of ~104 Hsa21 genes, is the most 
utilized mouse model and mirrors many of the phenotypes associated with DS including 
the craniofacial phenotype. Other less utilized models such as the Ts1Cje, Ms1Ts65, 
Ts1Rhr, Dp1Yey, Dp2Yey, and Dp3Yey also contain genes at dosage imbalance and but 
display less of the characteristic DS phenotypes (Sérégaza et al. 2006; Moore and Roper 
2007; Rueda et al. 2012).                     
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Another model, the Tc1 mouse, contains ~90% of Hsa21, but displays the extra 
chromosome only mosaically (Moore and Roper 2007; Rueda et al. 2012). 
 
1.6.1  Ts65Dn Mouse Model 
 The Ts65Dn mouse model contains an extra chromosome carrying the telomeric 
end of mouse chromosome 16 (Mmu16) attached to the small centromeric end of Mmu17 
(Davisson et al. 1993; Reeves et al. 1995) (Figure 1.2). The Ts65Dn mouse model was 
created by Muriel Davisson and colleagues at the Jackson Laboratory by producing 
reciprocal translocations through irradiation of the testes of male DBA/2J (D2) mice. 
After breeding males with C57BL/6J (B6) females, F1 offspring were screened for 
specific chromosome aberrations until a significant translocation was identified 
(Davisson et al. 1990). The specific translocation identified contained the extra 
chromosome carrying the telomeric end of Mmu16 attached to the small centromeric end 
of Mmu17 (Davisson et al. 1993; Reeves et al. 1995).  This extra chromosome contains 
12-15 Mb of Mmu16, a region conserved with the Hsa21 region 21q21-22.3 (Reeves et 
al. 1995; Baxter et al. 2000). Together, this produces a segmental trisomy which contains 
~104 Hsa21 homologues, making the Ts65Dn mouse at dosage imbalance for ~50% of 
total Hsa21 genes (Reeves et al. 1995; Hattori et al. 2000) (Figure 1.2). 
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1.6.1.1  Ts65Dn Phenotypes 
 Many studies have been performed to evaluate how the Ts65Dn mouse models 
human DS phenotypes. Thus far, the Ts65Dn mouse has been shown to mirror DS 
phenotypes in neurologic and brain deficiencies (Baxter et al. 2000), learning, memory 
and hearing deficits (Reeves et al. 1995), reduced birth weight (Roper et al. 2006b), a 
weakened skeletal phenotype  (Blazek et al. 2011), heart malformations (MOORE 2006), 
and alterations in craniofacial morphology (Richtsmeier et al. 2000; Richtsmeier et al. 
2002). Using 3D morphometric analysis, it has been shown that Ts65Dn mice mirror 
specific craniofacial dysmorphologies displayed in humans with DS including an overall 
reduction in head dimensions, a small midface, mediolaterally reduced orbital region, 
reduced maxilla and mandible, and brachycephaly (Figure1.3) (Richtsmeier et al. 2000). 
Ts65Dn mice also display brain deficiencies including a hypocellular brain, 
adisproportionately reduced cerebellum, and several neuropathological changes including 
a reduced number of Purkinje cells and granule cell neurons and reduced cell 
proliferation in the dentate gyrus (Insausti et al. 1998; Belichenko et al. 2004; Roper et 
al. 2006a). Ts65Dn female mice also display reduced fertility and male mice are 
functionally sterile. Increased perinatal lethality is also present in Ts65Dn mice (Roper et 
al. 2006b).  Although on average, ~50% of pups in each litter are trisomic at birth, many 
trisomic pups die after birth, leaving only ~30% of trisomic pups in each litter by three 
weeks postnatally (Reeves et al. 1995; Moore 2006; Roper et al. 2006b). 
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1.7  Neural Crest and Craniofacial Development 
 Neural crest cells (NCC) are a pluripotent cell population that differentiates into a 
variety of cell types and provides the main source of craniofacial mesenchyme for the 
formation of the craniofacial skeleton.  In mammals, NCC originate from the tip or ‘crest’ 
of the open neural fold which closes to become the neural tube (NT) (Santagati and Rijli 
2003)(Figure 1.4). Depending on the region of the NT from which NCC emigrate, NCC 
will become cranial, cardiac, trunk, or vagal NCC, each of which will differentiate to 
become diverse sets of tissue types.  In order for NCC to form their intended tissue types, 
several steps must occur including migration of sufficient NCC from the NT to their 
intended destination, differentiation into intended cell types, and successful proliferation 
of the cells in the developing tissue (Figure 1.5). In order for cells to differentiate and 
become a specified cell type, cells must be induced to a specific cell fate by an 
extracellular inductive signal such as bone morphogenic protein (BMP) or fibroblast 
growth factor (FGF) (Knecht and Bronner-Fraser 2002).  These signals differ between 
developing environments and make possible the development of multiple cell and tissue 
types from uniform pluripotent NCC lines.  NCC migrating from the region of the NT 
near the developing head arise from the diencephalon, midbrain, and hindbrain to form 
cranial NCC.  Cranial NCC have the ability to differentiate into various mesenchymal 
derivatives such as cartilage, bone and connective tissue in the head, in addition to 
neurons and glia cells of the peripheral nervous system (Knecht and Bronner-Fraser 
2002; Zhao et al. 2006).  Rostral cranial NCC form the frontonasal skeleton while cranial 
NCC migrating to the pharyngeal arches differentiate to form the cartilage and bone of 
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the jaw, middle ear, and neck (Santagati and Rijli 2003) (Figure 1.6).  In the formation of 
the mandible, cells travel from the NT to populate the first pharyngeal arch (PA1), the 
closest pharyngeal arch to the developing head (Roper and Reeves 2006) (Figure 1.7).  
Understanding the role of NCC in craniofacial development may help to identify the 
origins of NCC-related deficiencies causing many of the DS phenotypes. 
 
1.7.1  Mandibular and First Pharyngeal Arch Phenotype 
 Individuals with DS display a dysmorphic, undersized mandible compared to 
normal individuals that causes difficulties with eating, breathing, speech, and sleep 
(Richtsmeier et al. 2000). In Ts65Dn mice, the PA1, the NCC derived structure that 
develops into the mandible, is smaller in trisomic embryos by embryonic day 9.5 (E9.5) 
(Figure 1.8). In Ts65Dn embryos aged 9.25 days from conception (E9.25), the size of the 
PA1 is comparable to euploid littermates. However, by E9.5 (six hours later) the size of 
the PA1 in trisomic embryos becomes reduced in both the number of NCC and overall 
volume of the PA1 (Roper et al. 2009).  This deficiency is present from E9.5 onward, 
persists at E13.5, and is never recovered. These deficiencies arise from a decrease in the 
number of NCC migrating from the neural tube, a reduction in number of proliferating 
cells, and generation of new cells within the PA1 (Roper et al. 2009).  These findings 
suggest that gene dosage imbalance caused by trisomy occurring in the 6 hour window of 
development between E9.25 and E9.5 alters development of NCC-derived tissues through 
the altering gene networks involved in NCC migration and proliferation. 
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1.8  DYRK1A: A Candidate Gene for Down Syndrome 
 Much of the recent DS research has focused on identifying candidate genes or 
gene regions found on Hsa21 as the cause of specific DS phenotypes. Dual-specificity 
tyrosine phosphorylation kinase 1A (DYRK1A) is a DS candidate gene found in three 
copies and located on the 21q22.2 region of Hsa21. It has been implicated to contribute to 
many of the DS phenotypes, specifically to alterations in brain and intellectual ability 
associated with DS (Courcet et al. 2012).  DYRK1A is a serine-threonine kinase known to 
phosphorylate several transcription factors and functions as a cell cycle regulator (Soppa 
et al. 2014).  Specifically, it regulates proteins involved in brain and neuronal 
development (Tejedor and Hammerle 2011) including neuronal differentiation and has 
been linked to several neurodegenerative diseases including Alzheimer’s disease (Wegiel 
et al. 2011; Mazur-Kolecka et al. 2012).  DYRK1A is overexpressed ~1.5-fold in many 
tissues including human DS fetal brains and its homologue in mice has been shown to be 
overexpressed in a temporal spatial dependent manner in many developing tissues in 
Ts65Dn mice and embryos including the Ts65Dn E9.5 PA1 (Deitz, S. Unpublished 
Data). Overexpression of Dyrk1a in mice has been shown to lead to learning and memory 
deficits (Altafaj et al. 2001) and brain developmental abnormalities (BRANCHI et al. 
2004), including delayed neuronal differentiation (Kurabayashi and Sanada 2013), and 
altered neurogenesis (Thomazeau et al. 2014). It has also been implicated to cause 
alterations in cell cycle regulation (Branchi et al. 2004; Chen et al. 2013; Soppa et al. 
2014) cause motor dysfunction (Martinez de Lagran et al. 2004), and potentially alter 
craniofacial development (Solzak et al. 2013). Research suggests that overexpression of 
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Dyrk1a protein destabilizes gene pathways involved in development and cell cycle 
regulation resulting in these phenotypes.  In particular, overexpression of Dyrk1a protein 
is thought to destabilize an important developmental regulatory circuit involving NFATc, 
a nuclear factor of activated T-cells (Arron et al. 2006) (Figure 1.9). NFATc is a 
regulator of vertebrate development with known roles in development of cardiac tissue, 
muscle, nervous system, and in certain immune responses. The 1.5-fold overexpression 
of Dyrk1a is thought to prevent nuclear occupancy of NFATc, causing a failure to 
activate NFATc transcription factors involved in development. Tests in NFATc deficient 
mice suggest reduced NFATc levels cause many of the DS phenotypes. In addition to 
NFATc, Dyrk1a also phosphorylates other proteins including APP and TAU, known to 
be involved in Alzheimer pathogenesis, and CYCLINL2, involved in cell cycle 
regulation (Figure 1.10).  A great deal of recent research has focused on correcting 
Dyrk1a overexpression in mice to test the hypothesis that Dyrk1a overexpression is 
sufficient to induce many of the DS phenotypes. By normalizing Dyrk1a levels through 
alterations of Dyrk1a copy number or Dyrk1a protein expression in transgenic mice, 
many studies have reported improved learning (Souchet et al. 2014) improved or 
corrected brain phenotypes (Altafaj et al. 2013; Pons-Espinal et al. 2013) and motor 
alterations (Ortiz-Abalia et al. 2008). Together these studies implicate that normalization 
of Dyrk1a protein overexpression has the potential to improve not only brain, learning, 
and motor deficits, but other less-studied DS phenotypes as well. 
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1.9  EGCG as a Dyrk1a Inhibitor to Correct Down Syndrome Phenotypes 
 Epigallocatechin-3 gallate (EGCG) is a small molecule inhibitor of the DYRK1A 
protein, and has been tested as a clinically translatable way to normalize DYRK1A 
overexpression and correct phenotypes associated with DS  (Bain et al. 2003). EGCG is 
the major polyphenol found in green tea and constitutes 9-13% of its total dry weight 
(Dufresne and Farnworth 2001) (Figure 1.11). EGCG has well known health benefits due 
to its antioxidant properties and protection from metabolic syndrome, many types of 
cancers,  neuroprotection,  improvements in cognitive function, bone health, and reduced 
risk for cardiovascular disease (Nagle et al. 2006; Hodgson and Croft 2010; Williamson 
et al. 2011).  EGCG has recently been investigated as a potential therapeutic for DS 
phenotypes as it is able to inhibit DYRK1A protein activity and potentially normalize 
DYRK1A levels (Bain et al. 2003; Adayev et al. 2006; De la Torre et al. 2014).   There 
are conflicting hypotheses as to how EGCG inactivates DYRK1A. Some studies suggest 
that EGCG inhibits DYRK1A protein activity by binding the ATP pocket of the protein, 
preventing it from phosphorylating its downstream targets (WANG ET AL. 2012) while 
others suggest it is a non-competitive inhibitor with EGCG and that it binds to the X-XI 
kinase domain (Adayev et al. 2006). Studies have shown that EGCG is able to increase 
proliferation rates in Dyrk1a overexpressing cells from Ts65Dn embryos making it a 
useful treatment in vitro.  EGCG is also able to cross the blood-brain and placental 
barriers making it a viable treatment to correct effects of Dyrk1a overexpression in vivo. 
In vivo studies with mice have shown that EGCG can correct brain and cognitive deficits 
in mice overexpressing Dyrk1a (Adayev et al. 2006; Guedj et al. 2009; Wang et al. 2012; 
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Pons-Espinal et al. 2013; De la Torre et al. 2014) suggesting it may be effective as a 
modifier of phenotypes linked to Dyrk1a overexpression. 
 Harmine, another small molecule DYRK1A inhibitor, has also been investigated 
for its ability to inhibit DYRK1A protein activity. This molecule has been found to 
inhibit DYRK1A activity and Tau phosphorylation at multiple Alzheimer’s disease 
related sites (Frost et al. 2011). However, harmine is toxic in vitro and causes 
chromosomal alterations even at low levels and would not provide a clinically 
translatable therapy to normalize phenotypes related to the overexpression of DYRK1A 
(Boeira et al. 2001). EGCG has emerged as one of the most safe inhibitors of DYRK1A 
compared to other screened kinase inhibitors (Adayev et al. 2006). 
 
1.10  Next Generation Sequencing 
 Next generation sequencing (NGS) is a recent and growing technology that allows 
the DNA or RNA to be sequenced to determine the order of nucleotide bases. This 
technology has been revolutionary in identifying biological structure and function, 
creating maps of evolutionary conservation, identifying gene transcription, chromatin 
structure, methylation patterns, genetic variation, association to inherited diseases, and 
gene alterations in cancer, in addition to better defining the roles of protein-coding genes, 
non-coding RNAs and regulatory sequences (Lander 2011). Genome-wide expression 
analyses (RNA-seq) have been especially utilized in DS to identify how gene expression 
in DS varies (Marguerat and Bahler 2010) from both DS and non-DS samples matched in 
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as many parameters as possible such as age, gender and tissue type to compare gene 
expression levels.  Previous microarray studies have found that gene expression varies 
widely across tissue types and indicate that both trisomic and non-trisomic genes are 
dysregulated in DS to some degree in trisomic tissues (Li et al. 2012).  More recent NGS 
studies have additionally suggested that other genomic elements may play a role in 
causing dysregulation of developmental pathways in DS including non-coding RNA 
species such as snoRNAs and microRNAs (Costa et al. 2011). There is also evidence that 
trisomy may cause the alternative splicing of genes which may further alter gene 
dysregulation  (Toiber et al. 2010; Wegiel et al. 2011).  Together, this research provides a 
background for comparison of future gene expression studies in various tissue-specific 
and temporally dependent gene expression profiles of DS. The continuation of gene 
expression analysis in DS provides further understanding of genotype-phenotype 
correlations which may aid in development of gene-targeted therapies for DS phenotypes. 
 
1.11  Hypothesis 
 We hypothesize that Dyrk1a plays a role in causing deficient cell numbers in the 
E9.5 trisomic PA1, and is a key gene in the development of the small dysmorphic 
mandible displayed in DS. Because Dyrk1A is overexpressed ~1.5-fold in E9.5 trisomic 
PA1 and NT, we hypothesize it may contribute to NCC migration and proliferation 
deficits in the PA1 due to gene-dosage imbalance.  We hypothesize that cell deficits in 
Ts65Dn E9.5 PA1 will be ameliorated when pregnant Ts65Dn mothers are treated orally 
with a low dose of EGCG from G0 – G9.5. 
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1  Animal Housing 
 Female B6EiC3Sn a/A-Ts(1716)65Dn (Ts65Dn) and female and male C57Bl/6J 
(B6) and C3H/HeJ (C3H) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). B6C3F1 mice were bred by crossing B6 females with C3H males.  A 
colony of Ts65Dn males and females were generated and maintained at Indiana 
University-Purdue University Indianapolis (IUPUI) by crossing Ts65Dn females with 
B6C3F1 males.  Ts65Dn females and B6C3F1 females were also used in embryonic 
studies.  Male B6CBA-Tg(Wnt1-lacZ)206Amc/J (Wnt1-LacZ)  mice were also purchased 
from the Jackson Laboratory and maintained at IUPUI for embryonic studies. All 
Ts65Dn embryos and offspring were genotyped using PCR as described below. All 
animal housing and other experimental procedures conformed to IACUC regulations. 
 
2.2  Genotyping of Ts65Dn Mice and Embryos 
 Ts65Dn mice and embryos were genotyped using the breakpoint PCR genotyping 
protocol described by Reinholdt et al., 2011. Since the trisomic translocated chromosome 
is the distinguishing factor between Ts65Dn and euploid mice, the PCR detects the 
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translocation breakpoint between the telomeric end of Mmu16 attached to the 
centromeric end of Mmu17.  The forward primer binding on the Mmu17 side of the 
translocation site was Chr17fwd: 5’-GTGGCAAGAGACTCAAATTCAAC-3’ and the 
reverse primer binding on the Mmu16 side Chr16rev: 5’-
TGGCTTATTATTATCAGGGCATTT-3’. This primer set amplifies a 275 bp product 
from the translocation site. Positive control primers IMR1781: 5’-
TGTCTGAAGGGCAATGACTG-3’ and IMR1782: 5’-
GCTGATCCGTGGCATCTATT-3’ were used to amplify a 544 bp product. All four 
primers were obtained from Invitrogen (Carlsbad, CA). In a 25 µl reaction total, primers 
were used at a final concentration of 0.4 µM each. 1.5 µl of DNA at a concentration of 
75-125 ng/µl was used in each sample for both mouse and embryo DNA.  PCR cycling 
conditions were 94°C for 2 minutes, and 35 cycles at 94°C for 45 seconds, 55°C for 45 
seconds, and 72°C for 60 seconds, with a 72°C for 7 minutes extension, and 4°C hold 
(REINHOLDT et al. 2011). PCR products were separated for 25 min at 105 volts on a 1.5% 
agarose gel containing SYBR Gold DNA Staining Solution (Invitrogen, Carlsbad, CA). 
 
2.3  Generation of Ts65Dn Embryos 
 Female Ts65Dn mice were checked for estrus and bred to either B6C3F1 or 
homozygous Wnt1-LacZ males. To perform matings, Ts65Dn females were placed in a 
male mouse’s cage overnight for 15-20 hours. Females were checked for a vaginal plug 
the next morning, with 12:00 pm on the day of the mating identified as E0.5 to ensure 
timed mating. Females were then removed from breeding partners and single-housed for 
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nine days after the plug was identified, when embryos were staged at embryonic day 9.5 
(E9.5). After nine days, mothers were euthanized with isoflurane (Vedco, Inc., St. Joseph, 
MO) between 10am and 2pm and cervical dislocation performed to ensure brain function 
was severed and the mouse was deceased. Before embryos were removed, the mother’s 
abdomenal region around the removal site was sprayed with 70% ethanol. Embryos were 
removed and placed in 1% Phosphate-Buffered Saline (PBS) (Mediatech, Inc., Manassas, 
VA) in a petri dish and placed on ice to induce hypothermia.  Embryos were dissected in 
individual petri dishes containing PBS using forceps and a dissecting microscope.  Yolk-
sac tissue was removed for genotyping at time of dissection as the tissue is fetally, not 
maternally, derived and allows embryonic tissue to be left intact.  Somite numbers of 
each embryo were counted along the dorsal side of the embryo at time of dissection and 
used to determine developmental stage. Somites are derived from the mesoderm and 
differentiate to become cartilage, bone, muscle, and dermis throughout the body (Christ 
and Ordahl 1995) and can be used to stage the intrinsic development of the embryo 
(Venters et al. 2008). This is helpful as the 15-20 hour breeding period leaves room for 
variation in the embryo’s developmental stage reached by E9.5.  Better comparison of 
developmental processes is achieved when embryos are somite-matched. Embryos were 
processed as described below and embryos with 21-24 somites used for comparison in 
our studies. A small group of 18-20 somite embryos were included in our study; however 
data for these embryos were analyzed and presented separately. 
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2.4  In-Vivo EGCG Treatment 
 To assess the effects of prenatal EGCG on correcting NCC deficits in the 
developing PA1, pregnant Ts65Dn mothers were treated with EGCG and embryos were 
removed at E9.5 for tissue specific analysis following treatment to observe its effects on 
PA1 development. 
 
2.4.1  Preparation of EGCG 
 30 g of purified EGCG (>95%) (Sigma-Aldrich, St. Louis, MO) was dissolved in 
2 mL PBS to create a 15 mg/mL solution. Pregnant Ts65Dn and euploid mice bred to 
either Wnt1-LacZ males or B6C3F1 males were treated with EGCG orally using one of 
two treatment regimens.  Mice were treated with EGCG at concentrations well below 
established genotoxicity levels (Isbrucker et al. 2006).  
 
2.4.2  G7-G8 EGCG Treatment 
 Female Ts65Dn and euploid mice bred to Wnt1-LacZ males were weighed at time 
vaginal plug was observed. Females gaining at least 1-1.5 grams by seven days after the 
plug was observed were considered pregnant and were treated with EGCG or PBS as a 
control. Treatment was administered by oral gavage with a 22-gauge needle on 
gestational day 7 and day 8 (G7- G8) after the plug was observed and given twice daily 
with approximately 8 hours between treatments for a total of 4 treatment administrations. 
25 
 
Either PBS was administered as a control treatment or EGCG was administered at a 
concentration 200mg EGCG/kg body weight (a dose equivalent to 100 times the average 
daily EGCG dose in green tea) twice per day for a total of 400mg/kg/day.  Mice were 
monitored before, during and after treatment.  Treatment was discontinued in cases where 
mice appeared to be lethargic or less responsive following treatment and mice were 
removed from the study. On G9.5, mothers were sacrificed and embryos dissected out for 
processing as described below. 
 
2.4.3  G0-G9.5 EGCG Treatment 
 Female Ts65Dn and euploid mice were bred to Wnt1-LacZ or B6C3F1 males. At 
the start of the study, only Wnt1-lacZ euploid males were used for embryo generation, 
however, it became both difficult to generate embryos using these males and to generate 
embryos that were of sufficient developmental age. To continue our study, B6C3F1 
euploid males, used to maintain the Ts65Dn colony, were bred with Ts65Dn females to 
produce Ts65Dn/B6C3F1 embryos.  Data generated from embryos fathered by each set 
of male mice was analyzed separately, as differences in genetic background can influence 
developmental phenotypes (DEITZ and ROPER 2011).  Female mice were weighed at the 
time the vaginal plug was observed at G0.5 and at subsequent days 7, 8, and 9. EGCG 
treatment was prepared by dissolving 124 µL of 15mg/mL EGCG prepared as described 
above, into 20mL of tap water (a dose equivalent to 10 times the average daily EGCG 
dose in green tea) for a final concentration of 0.094mg EGCG/ml and administered ad 
libitum from G0-G9.5 following observation of the vaginal plug.  Treatment was changed 
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every two days, at which time the amount of treatment consumed was measured and 
recorded.  Mothers gaining at least 1-1.5g by day 8 and an additional ~0.5g from G8 to 
G9 were sacrificed on G9.5 and embryos dissected out as described above.  Because 
EGCG is known to degrade rapidly at room temperature (Table 2.1), rate of degradation 
was included in calculations of the average amount of EGCG consumed by mothers 
treated from G0 – G9.5 (Table 3.1). In other studies in our lab, phosphoric acid has been 
routinely added to EGCG treatment as a pH-lowering stabilizing agent, significantly 
reducing the natural degradation of EGCG in solution. However upon starting this 
stabilized EGCG treatment, normally fecundate mothers yielded no embryos at G9.5 over 
a period of several months.   Hence, the addition of phosphoric acid to EGCG treatment 
was discontinued, and all mothers included in the study were treated with EGCG only 
dissolved in water as described previously.  
 
2.5  Embryo Processing 
2.5.1  DNA Isolation of Yolk Sacs 
 Yolk sacs were removed during embryo dissection and placed in yolk sac lysis 
buffer (150mM NaCl, 20mM Tris-HCl ph 7.5, 5mM EDTA, 0.5% SDS, in ddH2O) with 
Proteinase K (12.5 µl of Proteinase K per 1 ml of yolk sac lysis buffer, 50 µL per yolk 
sac) (Bioline, Taunton, MA) and incubated overnight at 55°C. To each sample, 12.5 µl 
5M NaCl was added, each sample vortexed, then centrifuged at 13K rpm for 5 minutes. 
The supernatant was removed and placed in a new tube, 50 µl isopropanol was added, 
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and the sample was incubated for 5 minutes at room temperature before centrifuging at 
13K for 15 minutes. The supernatant was removed and discarded, 50 µl of cold 70% was 
added to the pellet, and the sample vortexed before centrifuging at 13K for one additional 
minute.  Samples were turned upside-down and gently blotted on a paper towel to remove 
the supernatant. Samples were dried upside down on a fresh paper towel for 10-15 
minutes. After samples were dry, 20 µl ddH2O was added to each sample and samples 
stored at 4°C until analyzed by PCR. 
 
2.5.2  Embryo Fixing and Embedding 
 Whole embryos were dissected out and placed in PBS in individual tubes until 
processing 0-3 hours later. To fix embryos, PBS was removed from each sample and the 
embryo washed with 500 µl of 0.1M phosphate buffer. Phosphate buffer was removed, 
500 µl fixing solution (0.2% gluteraldehyde with 5 mM EGTA and 2 mM MgCl2 in 0.1M 
phosphate buffer) added before incubating for 15-20 minutes depending on embryo size. 
Afterwards, fix solution was removed and embryos were washed three times for five 
minutes each in wash buffer (2 mM MgCl2, 0.02% Nonidet P-40 in 0.1 M phosphate 
buffer).  Ts65Dn/Wnt1-lacZ embryos were stained with 0.025% 5-bromo-4-chloro-3-
indoyl-β-D-galactopyranoside in 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide for 1.5 hours at 37°C. Embryos were then postfixed (Ts65Dn/B6C3F1 
embryos immediately following the three washes) with 4% paraformaldehyde overnight 
at 4°C. The next day, embryos were processed through a series of 500 µl washes.  
Embryos underwent dehydration washes in alcohol (10 min each in 50%, 70%, 70%, 
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95%, 95%, 100%, and 100% ethanol), clearing with xylenes (10 min each in 1:1 
xyelene:100% ethanol, xylene, xylene), and infiltration with paraplast (20 min each in 1:1 
xylene:paraplast, paraplast, paraplast). Embryos were then embedded parasagitally in 
paraffin and cured for one week at 4°C. 
 
2.5.3  Embryo Histology 
 Embryos were sectioned with a microtome in 18µm sections with 5 sections per 
microscope slide. The embryo sections were placed on a slide warmer overnight at 37°C 
and melted at 55°C for 1 hour to ensure sections adhered to the slides.  The sections were 
further processed through washes in CitriSolv (Fisher Scientific, Kalamazoo, MI) in three 
4 minute washes or until all paraffin wax was cleared from the slides, two 2 minute 
washes in 100% ethanol, 1 minute in 95% ethanol, and 1 minute in 70% ethanol. The 
slides were counterstained for 1 minute in 0.1% eosin (Fisher Scientific, Kalamazoo, MI) 
in 100% ethanol, two 10 and 15 second washes in 95% ethanol, two 2 minute washes in 
100% ethanol, and three 3 minute washes in CitriSolv.  Slides were removed from the 
fluid solution and coverslipped using 24 x 60 mm glass (Fisher Scientific, Kalamazoo, 
MI) and mounted with DPX mountant (VWR, West Chester, PA). Slides were cured for 
one week at room temperature before completing unbiased stereology. 
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2.6  Unbiased Stereology 
 Unbiased stereology was used to measure the volume of structures and tissues 
through systematic random sampling of the tissue. This was accomplished using 
Stereologer 2000 software and a Nikon Eclipse 80i microscope with moving stage 
(Japan).  Unbiased stereology was used to quantify total embryo volume, PA1 volume 
and number of NCC in the PA1 of embryos.  Unless otherwise stated, only embryos with 
21-24 somites were used for stereological analysis.  Cured slides with embryo sections 
were observed under a dissecting microscope to identify sections containing PA1 tissue 
and to identify any incomplete or missing sections before completing stereology. 
Parameters were adapted from  (Mouton 2002) to measure PA1 volume, NCC count, and 
total embryo volume.  PA1 volume was measured by sampling every other PA1 section 
starting with either the first or second section of PA1 tissue, chosen by a random number 
generator. As each sampled section thickness was assessed, NCC in the PA1 were 
quantified by counting the number of cells within a dissector spaced at intervals of 60 µm 
with dimensions of 150 µm
₂
 area and 8 µm depth with a 2 µm guard height.  Embryo 
volume was calculated by sampling every fourth section, with the start section from one 
to four determined by a random number generator.  Dimensions were set as a frame area 
of 25 µm
2
, 10 µm frame height, 2 µm guard height, 200 µm from spacing, 8000 µm
2
 area 
per point.  Average CE values for PA1 volume, NCC number, and embryo volume 
measurements were required to be <0.1 to be included in calculations.  Statistical 
differences were calculated using a one-tailed Student’s t-test. 
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2.7  Next Generation Sequencing and Analysis of RNA Isolates from Neural Tube and 
PA1 Tissue 
 To identify the effects of trisomy on differential gene expression during the origin 
of the NCC migration and proliferation deficits in the PA1 initiated between E9.25-E9.5, 
next generation sequencing was implemented from RNA isolates taken from the E9.25 
NT and E9.5 PA1 tissue of euploid and trisomic Ts65Dn embryos.  
 
2.7.1  RNA Isolation and Sample Pooling 
 Pregnant Ts65Dn trisomic mothers were sacrificed at G9.25 or at G9.5 and 
embryos removed and placed in PBS. Neural tube (NT) and first pharyngeal arch (PA1) 
tissue from E9.25 and E9.5 embryos, respectively, was dissected out in PBS using 30G 
needles. Total RNA was extracted from each sample using the Purifying RNA from 
Animal Tissues protocol found in the Pure Link Micro Kit from Invitrogen (Carlsbad, 
CA). RNA was treated with Ribominus to reduce rRNA.   
 Due to low RNA quantity of individual samples, 3 RNA samples were pooled in 
each library (1 E9.5 Ts65Dn pool had 4 samples) to provide the ~300ng/pool of RNA 
needed for sequencing. Samples were pooled based on similar developmental stages as 
compared by numbers of somites and using littermates where possible to limit variation 
between pools. Four libraries with 3-4 pooled RNA samples each were created in each of 
the following groups: E9.5 Trisomic PA1, E9.5 Euploid PA, E9.25 Trisomic NT, E9.25 
Euploid NT. 
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2.7.2  Sequencing, Quality Analysis, and Alignment 
 RNA extracts (concentration ~300 ng/pool) were prepared for sequencing using 
EZBead E120 Prep (Life Technologies). Sequencing, using 75bp read lengths, was 
performed on a SOLiD 5500XL sequencer at the Center for Medical Genomics in the 
Indiana University School of Medicine.  Analysis of RNA-sequence data was performed 
by Douglas Baumann and R.W. Doerge of the Department of Statistics at Purdue 
University using package edgeR (Robinson et al. 2010). Six data files were produced 
from the sequencing process, each representing one lane of a sequencing flow-cell, upon 
which 16 mRNA libraries (representing 16 biological samples) were barcoded and 
sequenced. The six data files produced from sequencing were presented in eXtensible 
SeQuence (.xsq) format, the Applied BioSystems proprietary data format for SOLiD 
sequencers. These files include a binary-style respresentaion of the base call (in SOLiD 
color-space) and a quality score for the base call. A Python library was used to convert 
and separate the data into CSFASTA and QUAL files to represent the base calls and 
quality scores respectively.  A quality score was recorded for every base sequenced. 
Phred Quality Scoring was used to determine bases with a high probability of being 
called incorrectly.  One sample showed slightly diminished quality compared to other 
samples, however, the design of the experiment (using barcoded samples sequenced on 
each available lane) allowed any potential resulting bias to be accounted for in the 
downstream modeling framework.  Reads were aligned to mouse reference genome 
(mm9) by Hai Lin and Yunlong Liu from the Center for Computational Biology and 
Bioinformatics at Indiana University-Purdue University Indianapolis (IUPUI). 
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2.7.3  Differential Expression Analysis 
 Differential expession analysis of the 22,813 genes detected by next generation 
sequencing was performed by Douglas Baumann and R.W. Doerge of the Department of 
Statistics at Purdue University. Because many of the genes detected demonstrated too 
little expression to be used for valid statistical analysis, all genes with average counts less 
than 5 across the samples within each embryonic day value were filtered out to yield a 
more powerful analysis.  To test for differential expression of each gene, Package edgeR 
(Robinson et al. 2010) was used, which uses a moderated negative binomial distribution 
to model the count data from the NGS experiment. The negative binomial model was 
used as it has the potential to accurately model discrete count data seen in NGS 
applications and allows more flexibility than other commonly used models such as a 
Poisson distribution. The negative binomial model was used to test for differential 
expression between the trisomic and euploid samples from E9.5 PA1 and E9.25NT 
separately.  Following the differential expression analysis, the number of transcript 
variants for differentailly expressed Mmu trisomic genes on Hsa21 was identified by 
searching both Ensembl and NCBI/GenBank databases. Using Ingenuity Pathway 
Analysis (IPA) software, functional analysis of differentially expressed genes and their 
potential relationship in related gene pathways was also performed. 
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2.7.4  MISO Analysis of Alternative Splicing Events 
 To identify alternative splicing (AS) events and gene isoforms, differentially 
expressed genes from our previous analysis were analyzed using a bioinformatic analysis 
called MISO (Managing Information for Sequence Operations).  To perform the MISO 
analysis RNA-seq reads were aligned to mm9 genome (version 9 of the mouse genome) 
and sorted.  All the .bam files from the differential expression analysis of the same tissue 
were merged and indexed by samtools.  A GFF file with annotations of alternative events 
was provided by MISO and .bam files were fed into MISO. Since reads in our RNA-seq 
data were single-end reads, we chose exon-centric analysis. MISO calculated 
exon/isoform expression levels (“Psi” / Ψ values) in each sample along with confidence 
intervals.  We then used MISO comparison to compute the differences of expressed 
exons across samples and Bayes factors to determine significance of changes (Δ Ψ). 
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CHAPTER 3. RESULTS: EFFECTS OF IN-VIVO TREATMENT WITH EGCG 
 
3.1  G7-G8 Treatment but Not G0-G9.5 Treatment with EGCG Improves Ts65Dn 
NCC Deficits 
Previously, our lab showed that in vitro, trisomic PA1 and NT cells treated with 
EGCG proliferated more than untreated cells in a dose-dependent manner (Deitz, 
Unpublished data) (Figure 3.1). Further experiments also showed in vivo oral treatment of 
Ts65Dn mothers with 400mg/kg/day of EGCG at G7 and G8 (gestational day 7 and 8) 
was sufficient to increase the increase the number of NCC in the PA1 and the size of the 
PA1 to near-euploid levels in E9.5 trisomic embryos (Figures 3.2, 3.3, 3.4)   
We hypothesized that treatment of pregnant Ts65Dn mothers with a lower dose of 
EGCG from the start of pregnancy to G9.5 would also correct NCC deficits in the PA1, 
the size of the PA1, and overall size deficits of developing trisomic embryos.  This 
treatment was designed to evaluate the safety and efficacy of EGCG as a potential 
prenatal supplement for human mothers and fetuses when taken at the start of pregnancy. 
We used B6C3F1 euploid fathers to breed with Ts65Dn females after difficulties with 
generation of embryos from Wnt1-LacZ euploid fathers.  We found that treatment with 
EGCG administered to Ts65Dn mothers at a concentration of ~12.2 mg/kg/day on 
average (Table 3.1) did not correct deficits in the PA1 of trisomic E9.5 embryos.  
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Average dosage of G0-G9.5 EGCG received through ad libitum treatment is detailed in 
Table 3.1 and Figures 3.5, 3.6.  Pregnant, non-pregnant, trisomic and euploid mothers all 
drank similar volumes of both EGCG and H2O. After treatment, there were no significant 
differences between the number of NCC in the PA1 or total embryo volume of trisomic 
embryos compared to those treated with water (Figures 3.7, 3.9).  There was however a 
significant increase in PA1 volume in euploid embryos from trisomic mothers (Eu/(Ts)) 
compared to untreated embryos of the same genotype (p=0.046)(Figure 3.8). 
There are several slight changes in trisomic EGCG treated embryos. There was a 
slight, but not significant decrease in EGCG treated Ts/(Ts) embryos compared to 
untreated embryos in both NCC number (p=0.061) and PA1 volume (p=0.058) compared 
to control embryos.  We attributed this difference to a reduced average somite number in 
trisomic embryos from trisomic mothers (Ts/(Ts)) treated with EGCG with an average of 
21.5 somites while the average somite number of all other groups ranged from 22.5-23.4.  
This implies that trisomic EGCG treated embryos may have been delayed during 
development, causing the lower NCC number due to a lapse in development.   There was 
also a slight but non-significant increase in embryo volume of Eu/(Ts) + EGCG embryos 
compared to untreated Eu/(Ts) embryos (p=0.089). 
Together, these results suggest that prenatal treatment with EGCG is sufficient to 
normalize NCC deficits when given twice in two days at G7 and G8 at a concentration of 
400 mg/kg/day, but not when administered continually at a concentration of ~12.2 
mg/kg/day from time of pregnancy. 
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3.2  G0 – G9.5 EGCG Treatment May Cause Developmental Delay in Embryos from 
Trisomic Mothers 
Somites are paired blocks of mesoderm developing on the dorsal side of the 
embryo and are used to measure developmental time (VENTERS et al. 2008).  To ensure 
embryos analyzed were at a similar developmental stage at E9.5, somite numbers were 
counted along the dorsal side of each embryo.  We analyzed the staging of all embryos in 
each litter used for our study to assess the effects of EGCG on developmental 
progression.  We observed several interesting differences in somite number depending on 
treatment and genetic background of the embryos. First, we found that Ts/(Ts) and 
Eu/(Ts) embryos, from both Wnt1-LacZ and B6C3F1 fathers, treated with EGCG from 
G0 – G9.5 showed significantly lower (p≤0.05) somite numbers compared to untreated 
embryos of the same genotype and Eu/(Eu) embryos in the same treatment group (Figure 
3.10).  No differences in somite numbers were observed in any embryos treated with PBS 
or EGCG from G7 – G8.  The data suggest that EGCG may slow development in 
embryos from trisomic mothers when given at an earlier time point or for a longer 
duration.  In euploid embryos from euploid mothers, average somite numbers were 
similar in both control and EGCG treatment groups suggesting EGCG does not affect 
developmental growth of embryos from euploid mothers.  
We also observed subtle differences in somite averages between embryos 
depending on their genetic background (Figure 3.10).  Embryos from Wnt1-LacZ fathers 
generally showed lower somite averages with more variation than embryos in similar 
treatment groups from B6C3F1 fathers.  Although significantly lowered somite numbers 
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were observed in G0 – G9.5 EGCG treatment groups in embryos of both backgrounds, 
the effect was also significantly more pronounced in Wnt1-LacZ embryos from trisomic 
mothers.  Wnt1-LacZ trisomic embryos from trisomic mothers had only 19.0 somites on 
average with only one embryo at 22 somites reaching the 21-24 somite stage needed to 
compare stereological data from embryos in other groups. For this reason, Wnt1-LacZ 
trisomic embryos were not included in further stereologic analysis. However, a 
comparison of 18-20 somite embryos (Figures 3.11, 3.12, 3.13) was made between 
EGCG treated Wnt1-LacZ trisomic and euploid embryos to assess differences between 
trisomic and euploid embryos.  Embryos from different paternal backgrounds (Wnt1-
LacZ and B6C3F1) were both used in our study as embryos became difficult to generate 
from Wnt1-LacZ males after a number of months. B6C3F1 males replaced Wnt1-LacZ 
males in production of embryos from Ts65Dn and euploid mothers. Data collected on 
embryos of both backgrounds was analyzed and compared separately to avoid 
confounding differences in data resulting from subtle but known differences attributed to 
genetic background  (Deitz and Roper 2011). 
 
3.3  No Differences Observed in 18-20 Somite Embryos Treated with EGCG 
Because trisomic embryos treated with high-dose EGCG displayed lower somite 
numbers than all euploid and untreated embryos, especially in Wnt1-LacZ embryos, data 
from this group could not be compared to the stereological data collected in our study 
from 21-24 somite embryos as embryos were not as developed.  We used embryos in this 
group to instead analyze data from 18-20 somite embryos only.  Embryos displaying 18-
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20 somites are typically representative of embryos staged prior to E9.5 as E9.5 embryos 
normally display 21-24 somites.  After E9.5, the PA1 volume and NCC count are 
proportionately smaller in trisomic embryos (Figure 1.8) permanently diverging from that 
of their euploid littermates. Consistent with this trend, we observed no differences in 
NCC number, PA1 volume, or embryo volume (Figures 3.11, 3.12, 3.13) between 
trisomic and euploid 18-20 somite embryos treated with EGCG.  These findings suggest 
that trisomic NCC deficits in the PA1 begin to develop during the period between the 18-
20 somite and 21-24 somite developmental time points.  These findings support previous 
research that no differences in trisomic and euploid PA1 exist at E9.25 but are present by 
E9.5 (ROPER et al. 2009).  Together, this data suggest that developmental changes that 
occur specifically between these somite ranges may lead to the altered trisomic PA1. 
Because these changes happen during this specific range, it provides an optimal window 
for treatment of embryos with EGCG to reduce or prevent NCC and PA1 deficits in 
trisomic embryos.
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CHAPTER 4. RESULTS: ANALYSIS OF NEXT GENERATION SEQUENCING 
DATA 
 
4.1  Differential Expression Analysis of Trisomic and Euploid NT and PA1 Tissue 
We performed next-generation sequencing of RNA isolates from trisomic and 
euploid E9.25 NT and E9.5 PA1 tissue to assess the gene expression differences 
occurring before and after NCC deficits arise in the trisomic PA1.  After low-count 
filtering, NGS detected expression of 13,883 E9.25 NT genes and 13,406 E9.5 PA1 
genes.  A differential expression analysis was performed on each of these tissue groups to 
identify differences in gene expression between trisomic and euploid samples in both 
E9.25 NT and E9.5 PA1. The purpose of this analysis was to identify potential genes and 
gene pathways specifically altered by trisomy. Of the 13,883 E9.25NT genes that passed 
the low-count filtering step, only 42 were differentially expressed between the trisomic 
and euploid samples (Table 4.1). Of the 13,406 E9.5PA1 genes, 336 genes were 
differentially expressed between the trisomic and euploid samples (Table 4.2).  Of the 42 
E9.25NT and 336 E9.5PA1 differentially expressed genes, none were found in common 
between the two embryonic days. 
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4.1.1  Filtering of Mmu16 and Hsa21 Differentially Expressed Genes 
Following the differential expression analysis, we filtered out differentially 
expressed genes found in 3 copies in our Ts65Dn mice or that had homologues on Hsa21. 
The purpose of this search was to identify which genes found in 3 copies may play a role 
in NCC deficits. We also wanted to evaluate whether trisomy results in dysregulation of 
only genes found in 3 copies or is sufficient to cause dysregulation of both trisomic and 
non-trisomic genes.  Of the 42 E9.25 NT differentially expressed genes, we found no 
trisomic genes in Ts65Dn or with homologues on Hsa21. All 42 differentially expressed 
genes are found on non-triplicated portions of the genome in 2 copies both in Ts65Dn 
and humans. Of the 336 E9.5 PA1 differentially expressed genes, 5 genes triplicated in 
Ts65Dn contained homologues on Hsa21 while the remaining 331 genes were found non-
trisomic portions of the genome in 2 copies in Ts65Dn and humans. The 5 genes 
containing Hsa21 homologues were Tiam1, Erg, Sh3bgr, Cldn8, and Mrap. 
We also included the Mmu16 genes Dyrk1a and Rcan1 in future transcript variant 
and MISO analysis as they are of particular interest to our research and have been shown 
to be differentially expressed in trisomic tissues by qPCR. However, differential 
expression of either gene was not detected in our NGS analysis. 
 
4.2  Transcript Variant Search for Differentially Expressed Trisomic Genes 
Transcript variants of a gene arise when a gene is spliced and different 
combinations of exons are included in the final gene product in a process called 
41 
 
alternative splicing. To further analyze the 5 trisomic E9.5 PA1 genes found in triplicate 
in Ts65Dn (Tiam1, Erg, Sh3bgr, Cldn8, Mrap) detected by the differential expression 
analysis, we searched for unique transcript variants of each gene.  We also included 
Dyrk1a and Rcan1 in our searches as they remain DS candidate genes in our study. In 
detecting transcript variants, we aimed to examine whether trisomy of Mmu16 was also 
able to cause differential splicing and expression of transcript variants in addition to its 
ability to induce differential gene expression.  Differential splicing and transcript variant 
expression induced trisomy may serve as a potential explanation for the variability in 
incidence and severity of trisomy-associated phenotypes in Ts65Dn and in the human DS 
population. 
Searches were performed using both Ensembl and NCBI Gene/GenBank 
databases as the number of unique transcript variants listed for each gene differed 
between databases (Table 4.3). Ensembl usually yielded a greater number of unique 
transcript variants which often included non-coding and putative transcripts while NCBI 
Gene/GenBank entries yielded the most well-established protein-coding transcripts 
form(s) of the gene.  We found multiple transcript variants for 4 out of 5 of the 
differentially expressed trisomic genes, and in both Dyrk1a (Figure 4.1) and Rcan1. The 
highest number of transcript variants found was in Tiam1 with 15 unique transcript 
variants using Ensembl and 3 using NCBI/Genbank. 
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4.3  MISO Analysis: Detection of Alternative Splicing Events 
After finding transcript variants of dysregulated trisomic genes, we further 
analyzed our NGS data to look for alternative splicing (AS) events that could lead to 
potential expression of a variety of transcript variants in both trisomic and non-trisomic 
differentially expressed genes. We used MISO to search for potential AS events among 
these genes.  We performed 4 comparisons to search for AS events among differentially 
expressed genes (Figure 4.3): (1) euploid and trisomic E9.5 PA1, (2) euploid and trisomic 
E9.25 NT, (3) euploid E9.25 NT and E9.5 PA1, (4) trisomic E9.25 NT and E9.5 PA1. For 
each comparison we found (1) 51 AS events that differed between trisomic and euploid 
E9.25 NT, (2) 24 AS events between trisomic and euploid E9.5 PA1, (3) 54 AS events 
between trisomic NT and PA1, and (4) 31 AS events between euploid NT and PA1.  
Between comparisons 1 and 2, only one of the AS events was shared between trisomic 
and euploid NT and PA1 tissues within the gene Cdc14b. Cdc14b is involved in cell 
cycle regulation and dephosphorylation of oncogene TP53. Interestingly, Cdc14b 
displayed different AS patterns between trisomic and euploid tissues.  Higher psi values 
of alternative splicing events in trisomic tissues indicated that longer isoforms of the gene 
were being transcribed. During the development of euploid PA1, levels of the longer 
Cdc14b isoform decreased, while their levels were maintained at relatively high levels in 
trisomic PA1 tissue.  In addition to Cdc14b, two AS events were shared between 
comparisons 3 and 4. These two genes found within both trisomic NT/PA1 and euploid 
NT/PA1 were Fgfr1op2 and Dph3.  Although transcript variants exist for the 4 of the 5 
trisomic E9.5 genes including Tiam1, Erg, Sh3bgr, Mrap and for Dyrk1a and Rcan1, we 
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did not find evidence of AS for any of these potential DS candidate genes. However, our 
analysis did reveal AS events and the expression of multiple transcripts from single genes 
throughout the genome between trisomic and euploid E9.25 NT and E9.5 PA1 tissue that 
may be of interest to future research efforts (Table 4.4).
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CHAPTER 5. DISCUSSION: EFFECTS OF IN-VIVO TREATMENT WITH EGCG 
 
5.1  Sufficient Dose of  EGCG Required to Ameliorate Trisomic Neural Crest Cell 
Deficits 
We hypothesized that prenatal treatment with EGCG could prophylactically 
improve or correct adverse phenotypes in Ts65Dn embryos while leaving euploid 
embryos unaffected. We found that short-term treatment during G7 and G8 with 400 
mg/kg/day of EGCG was able to improve NCC deficits in the mandibular precursor. 
However, longer-term treatment from G0-G9.5 at a lower dose, ~12.2 mg/kg/day EGCG, 
was unable to improve the trisomic NCC deficits in the mandibular precursor.  Evidence 
from our lab suggests that a higher dosage of EGCG administered at an optimal time 
point between G7-G8, as opposed to lower dosage administered for longer duration, is 
what likely improves trisomic phenotypes.  In unpublished research from our lab, we 
have found that 3 week old Ts65Dn mice treated with ~12.2 mg/kg/day of EGCG, 
comparable to our G0-G9.5 EGCG treatment regimen, for three weeks also yields no 
changes in cognitive abilities of Ts65Dn mice.  However, our lab has also shown that 
EGCG at a similar dose has been shown to improve the bone phenotype adolescent 
Ts65Dn mice aged 3-6 weeks.  Although EGCG given at ~12.2 mg/kg/day did not 
improve the cognitive or E9.5 PA1 deficits of Ts65Dn mice and embryos, respectively, a 
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recent study similar to the cognitive study completed by our lab (DE LA TORRE et al. 
2014) presented evidence that cognitive abilities of Ts65Dn mice were improved when 
treated with 90 mg/kg/day EGCG, higher than our low-dose of EGCG treatment.  Other 
research of embryonic development conducted with fetal alcohol syndrome (FAS), which 
has been shown to share similar developmental gene pathways and phenotypes to DS 
(Solzak et al. 2013), showed that reduced embryonic size in FAS mice can be improved 
in E9.5 embryos using the same dose (400 mg/kg/day) of EGCG and treatment duration 
as our G7-G8 EGCG regimen (Long et al. 2010). In this study, altered expression of 
neuronal marker genes in FAS was corrected with this EGCG treatment.  Together these 
results provide evidence that EGCG has the ability to improve NCC deficits associated 
with DS in mice when treated prenatally at a sufficient dose of EGCG. 
 
5.2  EGCG May Alter Embryonic Developmental Processes  
After quantifying somite numbers upon embryo removal to assess developmental 
staging of embryos, we observed that embryos from trisomic mothers treated with EGCG 
from G0- G9.5, but not from G7-G8, displayed lowered somite numbers compared to 
untreated embryos (Figure 3.10). These results suggest that EGCG may alter the 
progression of development during embryonic growth before E9.5.  Because the dose 
given with our G0-G9.5 treatment was less than that given from G7- G8, EGCG, when 
administered too early or for too long, has the potential to slow the progression of 
embryos and potentially alter developmental pathways.  Previous research from our lab 
has confirmed that EGCG may alter gene expression of important developmental genes 
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such as Rcan1, Shh, Ptch1, and Ets2 in addition to Dyrk1a (Figure 5.1).  Together this 
evidence suggests that EGCG may have the ability to affect other developmental 
pathways, in addition to its ability to potentially normalize Dyrk1a protein 
overexpression.  Although developmental size is decreased in embryos from trisomic 
mothers at G9.5, offspring have been born and seem to develop normally although no 
extensive phenotypic data have been collected.  Both positive and negative outcomes of 
the global effects of EGCG treatment will be better understood with future research.  
 
5.3  Translational Value of EGCG Research 
The purpose of our study with EGCG in mice was to test its effect on pregnant 
mice to evaluate its safety and efficacy as a potential prenatal treatment to be taken by 
human mothers to improve DS phenotypes.  It is imperative that EGCG be able to alter 
DS phenotypes while having no adverse effects on a normally developing fetus as a 
prenatal supplement would need to be taken before diagnostic testing for DS could be 
performed.  The NCC deficits that lead to craniofacial abnormalities, including the small 
mandible that contributes to impaired speech, breathing, and eating, arise by 4 weeks of 
pregnancy in humans, equivalent to G9.5 in Ts65Dn mice. By this time, a mother may 
either not yet know she is pregnant or be unable to obtain diagnostic testing for DS until 
9-10 weeks at the earliest.  
When extending the results of our study in Ts65Dn mice to the potential treatment 
of human fetuses, we show that EGCG does have the potential to be effective in 
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ameliorating NCC deficits in the mandibular precursor. However, our results showing 
that EGCG treated euploid mouse embryos from trisomic mothers display a larger PA1 
than untreated embryos, suggest that EGCG may have the potential to affect both fetuses 
with and without DS.  Our results showing that EGCG may slow embryonic 
developmental processes in embryos from trisomic mothers suggests that there is an 
effect of the trisomic maternal environment which affects the development of the 
embryos immediately before and at G9.5.  When translating this effect to a developing 
human fetus, the developmental delay effect displayed with EGCG treatment may not be 
of concern as the maternal uterine environment will most often be euploid, not trisomic.  
Despite these results, viable pups have been born to trisomic and euploid mouse mothers 
treated with either of our EGCG treatment regimens, suggesting that the increase in PA1 
size or the developmental delay may not be detrimental to developing embryos or their 
mothers.  Future research would be beneficial to determine any undetected genotype-
independent effects of EGCG that may be detrimental to a developing euploid embryo or 
mother to ultimately minimize risks of potentially harming a normally developing human 
fetus.   
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CHAPTER 6. DISCUSSION: ANALYSIS OF NEXT-GENERATION SEQUENCING 
DATA 
 
6.1  Detection of Trisomic and Euploid Differentially Expressed Genes on Mmu16 and 
Hsa21 
Although there are triplicated gene copies of only the genes found on Hsa21 in 
DS, there are conflicting theories about whether only trisomic genes are dysregulated in 
DS, or whether trisomic genes also cause the more global dysregulation of non-trisomic 
genes found in two copies.  Various studies have provided evidence of the global 
dysregulation theory in both Ts65Dn mice and humans.  These studies have shown 
dysregulation of both trisomic and non-trisomic genes in Ts65Dn cerebellum (Saran et al. 
2003), Ts65Dn E13.5 mandibular tissue (Billingsley et al. 2013), human DS fetal 
fibroblast cells (Letourneau et al. 2014) and in human endothelial progenitor cells (Costa 
et al. 2011).  Based on this and other research, we hypothesized that trisomy also causes 
global dysregulation of both trisomic and non-trisomic genes throughout the genome in 
Ts65Dn E9.25 NT and E9.5 PA1 tissue and may cause NCC deficits leading to the 
undersized mandible. Our differential expression analysis of NGS data of RNA isolates 
from both of the aforementioned tissues revealed differential expression of 53 non-
trisomic E9.25 NT genes, 364 non-trisomic E9.5 PA1 genes, and 5 trisomic E9.5 NT 
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genes. Because trisomy is the catalyzing event causing the gene dysregulation and the set 
of DS-like phenotypes, the evidence suggests that primary dysregulation of trisomic 
genes causes a secondary dysregulation of non-trisomic genes involved together in 
similar gene pathways. Together, this evidence suggests that gene dosage imbalance 
resulting from trisomy, causes global dysregulation of genes that is likely responsible for 
the array of variably expressed phenotypes that characterize DS.   
This analysis also identified 5 additional trisomic candidate genes (Tiam1, Erg, 
Sh3bgr, Cldn8, Mrap) that may play a role in the dysregulation of genes contributing to 
the NCC deficits in the E9.5 mandibular precursor. Because these genes were the only 
genes found in triplicate in our analysis, while all other dysregulated genes were found in 
two copies in both trisomic and euploid tissues, it suggests that Tiam1, Sh3bgr, Erg, 
Cldn8, and Mrap may play a role as the start of a gene cascade that causes more global 
dysregulation of genes throughout the genome.  Of the 5 genes, several have been linked 
to preexisting phenotypes associated with DS. Tiam1 and Sh3bgr have been linked to 
congenital heart defects in DS (Egeo et al. 2000; Liu et al. 2014), although there remains 
some debate about the involvement of Sh3bgr in DS heart defects.  In addition,  Erg has 
been linked to the acute megakaryoblastic leukemia that has a higher incidence in 
individuals with DS (Stankiewicz and Crispino 2013). Although not found in three 
copies, we also found altered expression of Gata1, a gene also implicated in acute 
megakaryoblastic leukemia in DS. Further investigation into the role of these genes will 
help to understand how trisomy may cause global gene dysregulation leading to NCC 
deficits in the PA1.   
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Although previous qPCR performed in our lab has indicated that the DS candidate 
gene Dyrk1a is upregulated 1.5-fold in E9.5 PA1, dysregulation of this gene was not 
detected in our differential expression analysis as we hypothesized.  We predict that these 
conflicting results may be due to in part to descrepancies in the qPCR performed. The 
probe used to detect the Dyrk1a transcript(s) binds to the junction between one set of 
exons only. Isoforms of the gene with this exon junction may be overexpressed ~1.5x in 
trisomic tissues. Any alternative isoforms of Dyk1a with the same exons spliced out may 
have been detected by RNA-seq, but not by qPCR suggesting that only specific isoforms 
of Dyrk1a may be overexpressed in trisomic tissues. 
 
6.2  Analysis of Transcript Variants and Alternative Splicing Events 
There is extensive evidence indicating that alternative splicing (AS) of some DS 
candidate genes may play a role in causing the variability in the expression of DS 
phenotypes.  An alternatively spliced gene has the potential to produce an altered protein 
with altered structure. This may affect its function and interaction with other proteins, 
ultimately leading to the possibility of an altered phenotype. Specifically, one study 
found that increased dosage of Dyrk1a can cause alternative splicing of Tau transcripts, a 
gene known to play a role in neurogenesis and in Alzheimer’s disease (Toiber et al. 
2010).  We attempted to detect whether the 5 E9.5 PA1 trisomic genes we detected in our 
differential expression analysis could be expressed as multiple transcript variants and 
found that 4 out of 5 of these genes did have multiple known transcript variants.  We also 
found known transcript variants of both Dyrk1a and Rcan1 (Figures 4.1, 4.2). 
51 
 
Although our MISO analysis revealed no AS of Tiam1, Sh3bgr, Erg, Cldn8, 
Mrap, Dyrk1a, or Rcan1, the analysis did reveal that AS is occurring in other genes 
between trisomic and euploid E9.25 NT and E9.5 PA1 tissue (Table 4.4).  With this 
analysis, we found approximately twice the number of AS events in the PA1 tissue 
compared to NT tissue when comparing trisomic and euploid tissues  (Figure 4.3, Table 
4.4). MISO analysis also revealed less AS events between trisomic NT and PA1 tissues 
than euploid NT and PA1, suggesting that more AS events are occurring in euploid 
tissues.  This suggests that trisomy may decrease the number of AS events.  This provides 
another mechanism whereby trisomy may lead to an altered phenotype in Ts65Dn mice 
and individuals with DS. 
Although more alternative splicing events seemed to occur in euploid and E9.5 
PA1 tissue, very few of the genes in which the AS events were occurring, were shared 
between these comparison groups.  However, three genes were shared between multiple 
comparison groups: Fgfr1op2, Dph3, and Cdc14b. Previous studies have shown that 
SNPs in the Fgfr1op2 gene are associated with long-term atrophy of the mandible 
(Suwanwela et al. 2011).  MISO analysis showed that Fgfr1op2 displays similar patterns 
of AS during mandible development in both trisomic and euploid mice indicating that 
this gene may play an important role in the development of the mandible. The Dph3 gene 
however, displayed different AS patterns between trisomic and euploid PA1 tissue. We 
predict that this difference in Dph3 gene splicing may contribute to NCC deficiencies in 
the PA1. The Cdc14b gene also displayed different AS patterns between trisomic and 
euploid tissues with longer isoforms being expressed in trisomic tissues. Because Cdc14b 
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has known involvement in cell cycle regulation, it is likely that alternative splicing of this 
gene may contribute to the decreased levels of NCC proliferation in the trisomic E9.5 
PA1. Together this analysis provides additional genes of interest for future research that 
have the potential to further understanding of the mechanisms by which trisomy causes 
the global gene dysregulation and the altered phenotypes of DS.  
 
 
6.3  Future Research 
Based on the research presented here, there are several opportunities for continued 
research.  Because EGCG treatment at G7 and G8 provides an optimal window in which 
to correct deficiencies and phenotypes associated with trisomy, continuation of the in 
vivo work with EGCG would be beneficial. To continue this research, postnatal 
assessment of pups whose mothers received EGCG on G7 and G8 at 400 mg/kg/day 
could establish whether the NCC improvements observed in the E9.5 PA1 translate to a 
normalized mandible postnatally and throughout adulthood. Pups treated prenatally with 
EGCG also provide optimal test subjects for cognitive, bone, and other phenotypic tests 
to assess alternative outcomes of prenatal EGCG treatment. 
Because the effects of EGCG were often not genotype specific, a more thorough 
assessment of EGCG’s effects on euploid embryos would be beneficial to future 
translational studies in humans.  It would be valuable to collect data on birth weight, 
vitals, bone structure, cognitive abilities, heart health and changes in gene expression at 
specific time points to determine the effects EGCG treatment could have on a normally 
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developing human fetus.  It would also be useful to understand how prenatal EGCG 
treatment affects mothers independent of developing embryos. 
To utilize the RNA sequence data and accompanying analyses performed here, a 
continued study of how transcript variants are affected by trisomy and lead to an altered 
phenotype would be valuable.  qPCR can be utilized to better characterize differing 
expression of Dyrk1a transcript variants in trisomic and euploid tissues.  Although 
Dyrk1a poses the greatest candidate for study, a study of the expression of other variable 
transcripts in DS genes of interest, including Tiam1, Sh3bgr, Erg, Cldn8, Mrap, or Rcan1 
would likely yield interesting findings about the trisomy-induced expression landscape.  
The RNA-seqeunce data, specifically the differential expression analysis, also 
provides a great deal of information with which to discover alternate gene networks 
involved in the alteration of trisomic phenotypes.  Because Tiam1, Sh3bgr, Erg, Cldn8, 
and Mrap were the only detected differentially expressed genes found in triplicate, 
finding other associated gene targets and pathways also dysregulated by trisomy will help 
to provide a more comprehensive understanding of additional gene networks that may be 
altered by trisomy.  A functional analysis of differentially expressed genes and pathways 
would also be useful. Together with this continued research, we can better link altered 
mechanisms to associated phenotypes in trisomy. Success of this research may provide 
new or better understood targets for gene therapy in efforts to normalize DS phenotypes 
and provide the opportunity for enhanced quality of life for individuals with DS.
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Table 2.1: Degradation Analysis of EGCG by HPLC-MS 
Chemical composition of EGCG prepared as described for the G0-G9.5 in-vivo ad libitum treatment was tested by HPLC-MS 
analysis after sitting at room temperature for 1, 24, and 48 hours. Data show that EGCG degrades rapidly at room temperature 
dissolved in water and undergoes significant reductions in concentration over time (Abeysekera, Roper, Unpublished data). 
 
Treatment Time point (hours) Expected Concentration 
(mg/mL) 
Calculated concentration 
(mg/mL) 
EGCG 1 1 1.001 ±0.0015 
 24 1 0.3349 ±0.014 
 48 1 0.1699 ±0.013 
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Table 3.1: G0 – G9.5 In-vivo Water and EGCG Ad libitum Treatment Data 
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B6C3F1 Trisomic H20 Yes 16 26.838 63.25 2.36 - -
B6C3F1 Trisomic H20 No 7 22.371 61.214 2.74 - -
B6C3F1 Trisomic EGCG Yes 4 27.540 71.125 2.58 6.615 26.769 12.318
B6C3F1 Trisomic EGCG No 3 22.633 64.833 2.86 6.030 29.649 13.644
B6C3F1 Euploid H20 Yes 9 27.433 66.833 2.44 - -
B6C3F1 Euploid H20 No 2 22.950 81.500 3.55 - -
B6C3F1 Euploid EGCG Yes 3 27.967 63.00 2.25 5.859 23.367 10.753
B6C3F1 Euploid EGCG - - - - - -
Average 12.238
* Calculated using individual sample values 
rather than group averages Standard Deviation* 2.195
Standard Error of the Mean (SEM)* 0.732
     7
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Table 4.1, continued 
Table 4.1: Differential Expression Analysis of Trisomic and Euploid E9.25 NT 
Gene Human 
Chromosome 
Homologue 
Gene Description logConc logFC P.Value adj.P.Val 
Ak2 1 adenylate kinase 2 -12.7943 0.213929 2.04E-06 0.007295 
Mrpl9 1 mitochondrial ribosomal protein L9 -13.5808 0.248396 2.14E-06 0.007295 
Stil 1 SCL/TAL1 interrupting locus -13.656 -0.2503 3.15E-06 0.007295 
Ubiad1 1 UbiA prenyltransferase domain containing 1 -14.9877 0.317282 2.33E-05 0.018553 
Dhcr24 1 24-dehydrocholesterol reductase -11.3304 0.141935 0.000151 0.049889 
Usp48 1 ubiquitin specific peptidase 48 -12.6019 -0.16291 0.000191 0.054019 
Aff3 2 AF4/FMR2 family, member 3 -13.6731 -0.39374 1.43E-05 0.017997 
Alms1 2 Alstrom syndrome 1 -12.4493 -0.18336 1.75E-05 0.018553 
Id2 2 inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein 
-12.435 -0.17623 3.65E-05 0.020333 
Snrpg 2 small nuclear ribonucleoprotein polypeptide G -15.7556 -0.3554 0.000173 0.053513 
Tbccd1 3 TBCC domain containing 1 -14.7609 0.282969 7.88E-05 0.035298 
Smarcad1 4 SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, subfamily a, 
containing DEAD/H box 1 
-12.3527 -0.20872 7.93E-07 0.005504 
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Table 4.1, continued 
Ostc 4 oligosaccharyltransferase complex subunit -12.9873 0.175576 0.000181 0.053811 
Lin54 4 lin-54 homolog (C. elegans) -13.8964 -0.21105 0.000216 0.05668 
Dap 5 death-associated protein -16.2402 -0.46654 3.11E-05 0.019717 
Pim1 6 pim-1 oncogene -14.1993 0.391914 3.93E-05 0.020333 
Fam120b 6 family with sequence similarity 120B -15.0223 -0.30018 8.40E-05 0.036428 
Ier3 6 immediate early response 3 -20.3423 1.661395 0.000207 0.056385 
Zfp788 7 zinc finger protein 788 -14.8817 -0.34162 3.09E-06 0.007295 
Ephb6 7 Eph receptor B6 -15.6419 0.422153 4.95E-06 0.009821 
Mios 7 missing oocyte, meiosis regulator, homolog 
(Drosophila) 
-13.9587 -0.22248 0.000108 0.039944 
Ncapg2 7 non-SMC condensin II complex, subunit G2 -12.3973 -0.15811 0.000182 0.053811 
Efha2 8 EF-hand domain family, member A2 -16.82 -0.5728 2.18E-05 0.018553 
Lrrcc1 8 leucine rich repeat and coiled-coil centrosomal 
protein 1 
-13.8255 -0.22052 7.36E-05 0.034055 
Inpp5e 9 inositol polyphosphate-5-phosphatase, 72 kDa -14.6541 -0.42584 2.51E-05 0.018553 
Chmp5 9 charged multivesicular body protein 5 -13.9686 0.244407 2.67E-05 0.018553 
Igsf9b 11 immunoglobulin superfamily, member 9B -15.4905 -0.39395 7.72E-06 0.013396 
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Table 4.1, continued 
Prkcdbp 11 protein kinase C, delta binding protein -17.2982 0.880583 1.05E-05 0.016273 
Nfrkb 11 nuclear factor related to kappaB binding protein -14.2859 -0.25835 4.10E-05 0.020333 
Sdhd 11 succinate dehydrogenase complex, subunit D, 
integral membrane protein 
-13.3573 0.196824 0.000103 0.0398 
Pitpnm1 11 phosphatidylinositol transfer protein, membrane-
associated 1 
-16.9881 0.722254 0.000129 0.044707 
Adipor2 12 adiponectin receptor 2 -12.7504 0.189551 2.57E-05 0.018553 
Dynll1 12 dynein, light chain, LC8-type 1 -11.9128 0.165497 3.35E-05 0.020208 
Mlec 12 malectin -10.4517 0.137748 8.98E-05 0.036428 
Uhrf1bp1
l 
12 UHRF1 (ICBP90) binding protein 1-like -13.4865 -0.19601 0.000146 0.049312 
Kntc1 12 kinetochore associated 1 -12.5547 -0.16332 0.000193 0.054019 
Srsf9 12 serine/arginine-rich splicing factor 9 -13.1778 0.177621 0.000216 0.05668 
Akap11 13 A kinase (PRKA) anchor protein 11 -11.676 -0.21352 3.60E-08 0.0005 
Zdhhc20 13 zinc finger, DHHC-type containing 20 -13.093 -0.20282 2.22E-05 0.018553 
Idh3a 15 isocitrate dehydrogenase 3 (NAD+) alpha -13.5238 0.218021 3.12E-05 0.019717 
Mmp15 16 matrix metallopeptidase 15 -14.2572 0.230541 0.000166 0.052502 
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Table 4.1, continued 
Snrpd1 19 small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa 
-13.1576 0.189321 0.000112 0.039944 
Cacna1a 19 calcium channel, voltage-dependent, P/Q 
type,alpha 1A subunit 
-16.2249 -0.41273 0.000195 0.054019 
Gpcpd1 20 glycerophosphocholine phosphodiesterase GDE1 
homolog 
-14.7663 -0.43191 2.23E-05 0.018553 
Sez6l 22 seizure related 6 homolog (mouse)-like -17.7091 -0.85455 0.000112 0.039944 
Prps2 X phosphoribosyl pyrophosphate synthetase 2 -13.3607 -0.20733 3.97E-05 0.020333 
Rab33a X RAB33A, member RAS oncogene family -19.7235 1.514429 4.73E-05 0.022662 
Arhgap36 X Rho GTPase activating protein 36 -19.1589 -1.21519 8.94E-05 0.036428 
Abca8b  ATP-binding cassette, sub-family A (ABC1), 
member 8b 
-18.6885 -1.14695 1.23E-05 0.017076 
9530091C08Rik misc RNA RefSeq import -17.4606 -1.18283 2.45E-05 0.018553 
5830418K08Rik RIKEN cDNA 5830418K08 gene -12.5791 -0.17943 4.00E-05 0.020333 
Zfp639  zinc finger protein 639 -14.9305 -0.29308 9.18E-05 0.036428 
2610020H08Rik RIKEN cDNA 2610020H08 -16.0046 -0.39361 0.000157 0.050586 
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 Genes with no listed human chromosome homologue were genes found only in mouse. 
 
 
 
 
 
Table 4.2, continued 
 
    
Table 4.2: Differential Expression Analysis of Trisomic and Euploid E9.5 PA1 
Mmu Gene Human 
Chromosome 
Homologue 
Description logConc logFC P.Value adj.P.Val 
Tnnt2 1 troponin T2, cardia -19.3943 -3.71116 4.28E-10 4.50E-07 
Obscn 1 obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
-20.3212 -2.98365 1.55E-07 4.95E-05 
Cited4 1 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 4 
-16.7008 1.346293 1.90E-07 5.91E-05 
Nexn 1 nexilin (F actin binding protein) -19.2088 -1.95298 2.18E-07 6.48E-05 
Ryr2 1 ryanodine receptor 2 (cardiac) -17.3056 -1.68824 3.42E-07 9.86E-05 
Pklr 1 pyruvate kinase, liver and RBC -15.098 1.092896 3.46E-07 9.86E-05 
Dnm3os 1 DNM3 opposite strand/antisense RNA 
(non-protein coding) 
-13.3269 -1.38649 7.53E-07 0.000189 
Ermap 1 erythroblast membrane-associated protein 
(Scianna blood group) 
-14.6365 1.010909 1.54E-06 0.000323 
Rassf5 1 Ras association (RalGDS/AF-6) domain 
family member 5 
-20.1291 -2.74136 1.75E-06 0.000361 
Snord45c 1 small nucleolar RNA, C/D box 45C -14.5217 -2.03633 1.96E-06 0.000386 
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Table 4.2, continued 
Npr1 1 natriuretic peptide receptor A/guanylate 
cyclase A (atrionatriuretic peptide receptor 
A) 
-17.0636 -1.17861 2.05E-06 0.000399 
Actn2 1 actinin, alpha 2 -19.4995 -2.14574 2.19E-06 0.000412 
Pdzk1ip1 1 PDZK1 interacting protein 1 -19.752 1.864615 7.91E-06 0.001084 
Asb17 1 ankyrin repeat and SOCS box containing 
17 
-20.7567 2.653425 8.43E-06 0.001084 
Tgfb2 1 transforming growth factor, beta 2 -17.146 -1.1013 8.63E-06 0.001091 
Prkaa2 1 protein kinase, AMP-activated, alpha 2 
catalytic subunit 
-17.2456 -1.28588 1.44E-05 0.00167 
Snord55 1 small nucleolar RNA, C/D box 55 -9.81852 -0.91157 1.98E-05 0.002182 
Snord47 1 small nucleolar RNA, C/D box 47 -10.3862 -1.17075 2.25E-05 0.002437 
Plekha6 1 pleckstrin homology domain containing, 
family A member 6 
-17.4452 -1.22831 2.47E-05 0.002595 
Rgs5 1 regulator of G-protein signaling 5 -16.0702 -1.18922 2.87E-05 0.002891 
Mir199a-2 1 microRNA 199a-2 -18.9134 -1.56161 2.95E-05 0.002927 
Snora16a 1 small nucleolar RNA, H/ACA box 16A -15.2166 -1.10507 6.06E-05 0.005112 
Ppfia4 1 protein tyrosine phosphatase, receptor type, 
f polypeptide (PTPRF), interacting protein 
(liprin), alpha 4 
-17.114 -0.98584 6.75E-05 0.005586 
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Table 4.2, continued 
Casq1 1 calsequestrin 1 (fast-twitch, skeletal 
muscle) 
-20.1266 -1.9884 7.14E-05 0.005835 
Tnni1 1 troponin I type 1 (skeletal, slow) -17.8237 -1.57281 8.65E-05 0.006704 
Mir214 1 microRNA 214 -18.0589 -1.17483 9.37E-05 0.00708 
Ero1lb 1 ERO1-like beta (S. cerevisiae) -18.7867 1.26908 0.000168 0.010778 
Mgst3 1 microsomal glutathione S-transferase 3 -14.4252 0.87071 0.000203 0.012569 
Mir664 1 small nucleolar RNA, H/ACA box 36B -20.5081 -1.98906 0.000266 0.01556 
Snora36b 1 small nucleolar RNA, H/ACA box 36B -20.5283 -1.94876 0.000389 0.020779 
Snora61 1 small nucleolar RNA, H/ACA box 61 -10.1994 -0.969 0.000428 0.022485 
Tlr5 1 toll-like receptor 5 -19.8554 -1.58241 0.000438 0.022838 
Gja5 1 gap junction protein, alpha 5, 40kDa -15.9404 -0.96439 0.000617 0.02984 
Tspan2 1 tetraspanin 2 -15.8409 -0.79725 0.000638 0.030426 
Lmx1a 1 LIM homeobox transcription factor 1 alpha -16.9828 0.839984 0.000655 0.030993 
Spata1 1 Spermatogenesis-associated protein 1 -18.9247 -1.16716 0.000676 0.031598 
Atp1b1 1 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
-17.58 -1.03405 0.000791 0.035745 
Nfia 1 nuclear factor I/A -18.5734 -1.04941 0.00085 0.037465 
7
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Table 4.2, continued 
Klhdc8a 1 kelch domain containing 8A -19.6062 -1.38369 0.000865 0.037889 
Lmod1 1 leiomodin 1 (smooth muscle) -20.1146 -1.59609 0.001008 0.042475 
Tmod4 1 tropomodulin 4 (muscle) -19.5201 -1.32415 0.001044 0.04366 
Rgs4 1 regulator of G-protein signaling 4 -20.0033 -1.62651 0.001054 0.043902 
Rwdd3 1 RWD domain containing 3 -18.6117 -1.06331 0.001077 0.04444 
Brdt 1 bromodomain, testis-specific -19.4323 -1.2811 0.001176 0.047338 
Smyd1 2 SET and MYND domain containing 1 -16.7078 -3.15762 3.85E-09 2.46E-06 
Ttn 2 titin -14.5844 -3.27642 4.78E-09 2.79E-06 
Epas1 2 endothelial PAS domain protein 1 -16.5024 -1.32746 2.21E-06 0.000412 
Zc3h6 2 zinc finger CCCH-type containing 6 -19.0458 -1.48007 2.36E-05 0.002512 
Bcl11a 2 B cell CLL/lymphoma 11A (zinc finger 
protein) 
-18.8831 -1.3616 6.71E-05 0.005586 
Kcnh7 2 potassium voltage-gated channel, 
subfamily H (eag-related), member 7 
-19.7507 -1.66942 0.0001 0.007328 
Scn2a1 2 sodium channel, voltage-gated, type II, 
alpha subunit 
-19.8241 -1.64911 0.00014 0.009486 
Adcy3 2 adenylate cyclase 3 -16.3586 -0.86867 0.000146 0.009609 
7
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Table 4.2, continued 
Kif1a 2 kinesin family member 1A -16.4582 -0.82254 0.000158 0.010302 
Neurod1 2 neurogenic differentiation 1 -20.4275 -1.86875 0.000273 0.015788 
Nrxn1 2 neurexin 1 -18.2937 -1.39655 0.000303 0.016845 
Snord53 2 small nucleolar RNA, C/D box 53 -12.5501 -0.77546 0.00031 0.017169 
Rsad2 2 radical S-adenosyl methionine domain 
containing 2 
-18.0235 -1.03751 0.000379 0.020333 
Add2 2 adducin 2 (beta) -14.9901 0.694501 0.000443 0.022998 
Snord92 2 small nucleolar RNA, C/D box 92 -14.1181 -0.85214 0.000509 0.026026 
Snord70 2 small nucleolar RNA, C/D box 70 -14.6665 -0.8487 0.000613 0.02984 
Ifih1 2 interferon induced with helicase C domain 
1 
-20.3804 -1.71895 0.000805 0.036095 
Dusp28 2 dual specificity phosphatase 28 -16.8363 -0.88277 0.000833 0.036998 
Sphkap 2 SPHK1 interactor, AKAP domain 
containing 
-17.6319 -1.3177 0.000955 0.041173 
Pou3f3 2 POU class 3 homeobox 3 -17.4994 -1.02026 0.000989 0.042032 
Sned1 2 sushi, nidogen and EGF-like domains 1 -18.6901 -1.04018 0.001306 0.05118 
Slc8a1 2 solute carrier family 8 (sodium/calcium 
exchanger), member 1 
-15.5574 -0.99185 0.001368 0.052806 
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Table 4.2, continued 
Erbb4 2 v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
-20.2093 -1.61767 0.001433 0.053815 
Xirp1 3 xin actin-binding repeat containing 1 -21.7953 -6.04913 8.33E-12 2.79E-08 
Tdgf1 3 teratocarcinoma-derived growth factor 1 -21.5431 -4.54989 1.95E-08 9.03E-06 
Kcnab1 3 potassium voltage-gated channel, shaker-
related subfamily, beta member 1 
-20.4192 -2.47088 1.24E-06 0.000277 
Snora7a 3 small nucleolar RNA, H/ACA box 7A -12.0668 -1.6092 2.79E-06 0.000505 
Tnnc1 3 troponin C type 1 (slow) -19.7577 -2.32334 5.20E-06 0.00082 
Hesx1 3 HESX homeobox 1 -19.8931 2.128801 5.31E-06 0.000821 
Snord61 3 Small nucleolar RNA SNORD61 -15.4615 -1.19682 7.28E-06 0.001049 
Popdc2 3 popeye domain containing 2 -17.6838 -1.47734 8.93E-06 0.001119 
Cpne4 3 copine IV -20.0537 -2.14422 1.04E-05 0.001268 
Cspg5 3 chondroitin sulfate proteoglycan 5 
(neuroglycan C) 
-19.4511 1.657913 3.16E-05 0.003088 
Sema3b 3 sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3B 
-18.6522 -1.22154 0.000142 0.009536 
Snord2 3 eukaryotic translation initiation factor 4A2 -14.4243 -0.96997 0.000179 0.011221 
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Table 4.2, continued 
Adamts9 3 ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 
-14.8123 -0.83347 0.000183 0.01138 
Cacna1d 3 calcium channel, voltage-dependent, L 
type, alpha 1D subunit 
-16.743 -0.86018 0.000577 0.028343 
Manf 3 mesencephalic astrocyte-derived 
neurotrophic factor 
-13.0539 0.639832 0.00063 0.030277 
Slc15a2 3 solute carrier family 15 (H+/peptide 
transporter), member 2 
-17.2903 -1.0718 0.001073 0.0444 
Rpl29 3 ribosomal protein L29 -13.9511 0.70219 0.001272 0.050454 
Gypa 4 glycophorin A (MNS blood group) -14.5644 0.947541 5.62E-06 0.000846 
Fam198b 4 family with sequence similarity 198, 
member B 
-16.437 -1.0855 4.92E-05 0.004488 
Afp 4 alpha-fetoprotein -20.1511 2.107951 7.68E-05 0.006244 
Spp1 4 secreted phosphoprotein 1 -19.358 1.714514 0.000102 0.007352 
Cpeb2 4 cytoplasmic polyadenylation element 
binding protein 2 
-17.4279 -0.98508 0.000434 0.02273 
Ppargc1a 4 peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha 
-18.8714 -1.13089 0.000898 0.039198 
Mrps18c 4 mitochondrial ribosomal protein S18C -15.7633 0.678695 0.000953 0.041173 
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Table 4.2, continued 
Manba 4 mannosidase, beta A, lysosomal -18.4001 -1.0402 0.000979 0.041784 
Synpo2 4 synaptopodin 2 -16.4335 -0.78473 0.001146 0.046356 
Rnf150 4 ring finger protein 150 -16.1423 -0.67562 0.001383 0.052806 
Prlr 5 prolactin receptor -20.1183 -1.81043 0.000109 0.007665 
Uqcrq 5 ubiquinol-cytochrome c reductase, complex 
III subunit VII, 9.5kDa 
-15.1972 0.909517 0.000133 0.009072 
Gpr98 5 G protein-coupled receptor 98 -15.3883 -0.81406 0.000158 0.010302 
Lyrm7 5 Lyrm7 homolog (mouse) -18.481 -1.27124 0.000314 0.017347 
Gm2a 5 GM2 ganglioside activator -17.6991 -0.93009 0.000818 0.036555 
Ppp2r2b 5 protein phosphatase 2, regulatory subunit 
B, beta 
-18.6281 -1.05693 0.001324 0.051581 
Pdzd2 5 PDZ domain containing 2 -17.2126 -0.83746 0.001375 0.052806 
Col12a1 6 collagen, type XII, alpha 1 -16.5265 -2.07908 7.53E-11 1.68E-07 
Rhag 6 Rh-associated glycoprotein -15.6944 1.025598 4.20E-06 0.0007 
Syne1 6 spectrin repeat containing, nuclear 
envelope 1 
-15.8698 -1.12388 5.06E-06 0.000807 
Psmg4 6 proteasome (prosome, macropain) 
assembly chaperone 4 
-16.6822 1.00291 2.54E-05 0.002622 
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Table 4.2, continued 
Gata5 6 protein phosphatase 1, regulatory 
(inhibitor) subunit 14C 
-17.9052 -1.36242 3.07E-05 0.003028 
Pde7b 6 phosphodiesterase 7B -17.9421 -1.13017 5.92E-05 0.005052 
Phactr1 6 phosphatase and actin regulator 1 -16.8714 -0.94974 8.62E-05 0.006704 
Hist1h3a 6 histone cluster 1, H3a -12.4587 0.711003 0.000134 0.009115 
Hist1h3g 6 histone cluster 1, H3g -12.3733 0.682107 0.000246 0.014658 
Fam65b 6 family with sequence similarity 65, 
member B 
-19.5741 -1.44754 0.000303 0.016845 
Synj2 6 synaptojanin 2 -16.6093 -0.79155 0.000379 0.020333 
Hist1h2bn 6 histone cluster 1, H2bn -13.329 0.653368 0.000511 0.026035 
Klhl31 6 kelch-like 31 (Drosophila) -20.2386 -1.77631 0.00057 0.028278 
Snord66 6 Small nucleolar RNA SNORD66 -12.0523 -0.66791 0.000855 0.037595 
Syncrip 6 synaptotagmin binding, cytoplasmic RNA 
interacting protein 
-12.3561 -0.78791 0.001045 0.04366 
Rps18 6 ribosomal protein S18 -15.0631 -0.89117 0.001093 0.044964 
Hspa1b 6 heat shock 70kDa protein 1B -18.4259 1.026991 0.001098 0.044996 
Slc25a27 6 solute carrier family 25, member 27 -16.8749 -0.76603 0.001465 0.054774 
Cap2 6 CAP, adenylate cyclase-associated protein, -17.6622 -1.02046 0.001467 0.054774 8
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Table 4.2, continued 
2 (yeast) 
Myl7 7 myosin, light chain 7, regulatory -18.3004 -3.22894 4.06E-09 2.48E-06 
Upk3b 7 uroplakin 3B -19.4924 -2.33063 9.85E-08 3.33E-05 
Tbx20 7 T-box 20 -16.961 -1.79452 2.08E-07 6.33E-05 
Snord93 7 small nucleolar RNA, C/D box 93 -16.1858 -1.46131 4.91E-06 0.000793 
Ikzf1 7 IKAROS family zinc finger 1 (Ikaros) -16.0441 1.029381 2.07E-05 0.002253 
Smarcd3 7 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily d, member 3 
-16.8105 -0.94729 8.07E-05 0.006516 
Mrps24 7 mitochondrial ribosomal protein S24 -16.0475 0.883296 8.53E-05 0.00669 
Kcp 7 kielin/chordin-like protein -17.5511 -1.08004 8.86E-05 0.00679 
Hoxa2 7 homeobox A2 -18.3598 -1.65873 0.000109 0.007665 
Serpine1 7 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 1 
-18.1725 -1.09404 0.000177 0.011153 
Zpbp 7 zona pellucida binding protein -20.4236 -1.87945 0.000273 0.015788 
Tspan33 7 tetraspanin 33 -16.3572 0.847488 0.000279 0.016033 
Cacna2d1 7 calcium channel, voltage-dependent, alpha 
2/delta subunit 1 
-16.4657 -0.77395 0.000415 0.022011 
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Table 4.2, continued 
Magi2 7 membrane associated guanylate kinase, 
WW and PDZ domain containing 2 
-19.0241 -1.18505 0.000656 0.030993 
Kel 7 Kell blood group, metallo-endopeptidase -15.6864 0.745265 0.000792 0.035745 
Nrbp2 8 nuclear receptor binding protein 2 -17.2452 -1.34411 1.30E-07 4.26E-05 
Trim55 8 tripartite motif containing 55 -19.6456 -2.18783 6.95E-07 0.000183 
Nkx2-6 8 NK2 homeobox 6 -18.5756 -1.85234 1.50E-06 0.000323 
Car2 8 carbonic anhydrase II -13.2247 0.828071 1.13E-05 0.00135 
Gata4 8 GATA binding protein 4 -18.9711 -1.76994 1.54E-05 0.001768 
Foxh1 8 forkhead box H1 -18.5924 1.402238 2.35E-05 0.002512 
Sla 8 Src-like-adaptor -19.5881 1.65995 9.84E-05 0.007247 
Snord87 8 small nucleolar RNA, C/D box 87 -10.3935 -0.94958 0.000164 0.010626 
Pkhd1l1 8 polycystic kidney and hepatic disease 1 
(autosomal recessive)-like 1 
-15.5258 0.782422 0.000358 0.019488 
Cebpd 8 CCAAT/enhancer binding protein 
(C/EBP), delta 
-19.6996 -1.45498 0.000554 0.027829 
Plekha2 8 pleckstrin homology domain containing, 
family A (phosphoinositide binding 
specific) member 2 
-15.6334 -0.77929 0.000728 0.033189 
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Table 4.2, continued 
Scara3 8 scavenger receptor class A, member 3 -16.6706 -0.82181 0.000978 0.041784 
Tnc 9 tenascin C -15.504 -1.94483 2.04E-08 9.13E-06 
Ddx58 9 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
58 
-18.4821 -1.51925 1.13E-06 0.000261 
Pgm5 9 phosphoglucomutase 5 -18.6455 -1.81956 3.17E-06 0.000566 
Snora65 9 small nucleolar RNA, H/ACA box 65 -13.9262 -1.56057 3.30E-06 0.000575 
Gfi1b 9 growth factor independent 1B transcription 
repressor 
-17.8965 1.268166 1.15E-05 0.001359 
Snord90 9 small nucleolar RNA, C/D box 90 -19.4455 -1.46398 0.000219 0.013411 
Aqp3 9 aquaporin 3 (Gill blood group) -17.5192 1.030949 0.000289 0.016365 
Rusc2 9 RUN and SH3 domain containing 2 -18.0341 -0.97586 0.00052 0.026373 
Ldb3 10 LIM domain binding 3 -20.7898 -4.89824 1.74E-13 1.17E-09 
Ankrd1 10 ankyrin repeat domain 1 (cardiac muscle) -19.7468 -3.79277 1.16E-10 2.21E-07 
Acta2 10 actin, alpha 2, smooth muscle, aorta -14.9387 -2.29823 6.11E-08 2.27E-05 
Anubl1 10 zinc finger, AN1-type domain 4 -18.3849 -1.31915 1.44E-05 0.00167 
Usmg5 10 up-regulated during skeletal muscle growth 
5 homolog (mouse) 
-16.3156 1.027089 1.99E-05 0.002182 
Ppp1r14c 10 protein phosphatase 1, regulatory -19.4963 -1.89405 2.91E-05 0.002912 8
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Table 4.2, continued 
(inhibitor) subunit 14c 
Nebl 10 nebulette -17.3285 -1.29096 3.48E-05 0.003353 
Ret 10 ret proto-oncogene -20.0676 -1.88951 8.34E-05 0.006653 
Ptpre 10 protein tyrosine phosphatase, receptor type, 
E 
-19.1747 -1.4849 9.51E-05 0.007119 
Asah2 10 N-acylsphingosine amidohydrolase (non-
lysosomal ceramidase) 2 
-17.129 -0.9413 0.000343 0.018743 
Sfxn3 10 sideroflexin 3 -18.2395 -0.96483 0.001101 0.044996 
Uros 10 uroporphyrinogen III synthase -15.0043 0.626338 0.001521 0.056547 
Mybpc3 11 myosin binding protein C, cardiac -18.8463 -4.30097 2.24E-10 3.10E-07 
Eps8l2 11 EPS8-like 2 -16.337 -1.14236 6.74E-07 0.000181 
Neat1 11 nuclear paraspeckle assembly transcript 1 
(non-protein coding) 
-18.2393 -1.71351 7.60E-07 0.000189 
Tagln 11 transgelin -15.2906 -1.50629 5.33E-06 0.000821 
Snora3 11 small nucleolar RNA, H/ACA box 3 -16.1779 -1.53361 6.62E-06 0.000975 
Snord15a 11 small nucleolar RNA, C/D box 15A -11.5747 -1.53881 7.00E-06 0.00102 
Cd44 11 CD44 molecule (Indian blood group) -16.7495 -1.19218 1.40E-05 0.001648 
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Table 4.2, continued 
Hmbs 11 hydroxymethylbilane synthase -13.5345 0.759467 6.04E-05 0.005112 
Mical2 11 microtubule associated monoxygenase, 
calponin and LIM domain containing 2 
-17.9721 -1.1143 0.000209 0.01285 
Slc1a2 11 solute carrier family 1 (glial high affinity 
glutamate transporter), member 2 
-17.8241 -1.18071 0.0003 0.016803 
Tspan18 11 tetraspanin 18 -15.9822 -0.83139 0.000391 0.020781 
Naalad2 11 N-acetylated alpha-linked acidic 
dipeptidase 2 
-19.2215 -1.29067 0.000711 0.032745 
Scarna9 11 small Cajal body-specific RNA 9 -15.8258 -0.81474 0.000918 0.039974 
Wt1 11 Wilms tumor 1 -20.0854 -1.47569 0.00131 0.051185 
Abcg4 11 ATP-binding cassette, sub-family G 
(WHITE), member 4 
-17.4508 0.851724 0.001411 0.053302 
Snord67 11 Small nucleolar RNA SNORD67 -16.0266 -0.71269 0.001523 0.056547 
Dhh 12 desert hedgehog -20.3135 2.728132 5.16E-08 2.10E-05 
Tbx5 12 T-box 5 -20.8049 -2.87231 4.43E-07 0.000124 
Snora34 12 small nucleolar RNA, H/ACA box 34 -15.7914 -1.45704 7.84E-06 0.001084 
Pde3a 12 phosphodiesterase 3A, cGMP-inhibited -18.1716 -1.43315 8.38E-06 0.001084 
Kcna5 12 potassium voltage-gated channel, shaker-
related subfamily, member 5 
-17.4065 -1.09018 2.53E-05 0.002622 
8
8
  
 
 
 
 
 
Table 4.2, continued 
Art4 12 ADP-ribosyltransferase 4 -16.9158 0.986679 5.51E-05 0.00486 
Scarna10 12 small Cajal body-specific RNA 10 -15.1643 -0.82933 0.000102 0.007352 
Tdg 12 thymine-DNA glycosylase -15.6073 0.843566 0.000106 0.007483 
Nfe2 12 nuclear factor (erythroid-derived 2), 45kDa -16.531 0.860287 0.000266 0.01556 
Snora2b 12 small nucleolar RNA, H/ACA box 2B -17.88 -1.04011 0.000521 0.026373 
Esyt1 12 extended synaptotagmin-like protein 1 -15.9231 -0.80105 0.000659 0.030993 
Hebp1 12 heme binding protein 1 -15.8889 0.717942 0.001288 0.050791 
Snord22 13 Small nucleolar RNA SNORD22 -9.79836 -1.59489 7.45E-07 0.000189 
Mir15a 13 microRNA 15a -20.1032 -1.83316 0.000141 0.009487 
Mtus2 13 microtubule associated tumor suppressor 
candidate 2 
-18.2659 -1.22508 0.000169 0.010812 
Myh6 14 myosin, heavy chain 6, cardiac muscle, 
alpha 
-19.7578 -5.49998 1.46E-16 1.96E-12 
Myh7 14 myosin, heavy chain 7, cardiac muscle, 
beta 
-16.0569 -2.95322 1.59E-09 1.18E-06 
Nkx2-1 14 NK2 homeobox 1 -20.4824 -3.07691 2.60E-08 1.12E-05 
Snord8 14 small nucleolar RNA, C/D box 8 -14.0862 -1.08644 9.65E-06 0.001198 
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Table 4.2, continued 
Mir654 14 microRNA 654 -20.2893 -1.89894 0.000166 0.010681 
Fos 14 FBJ murine osteosarcoma viral oncogene 
homolog 
-15.6817 1.021225 0.00056 0.028003 
Mir770 14 microRNA 770 -17.0986 -0.85874 0.000591 0.028923 
Mir1193 14 microRNA 1193 -18.6441 -1.08073 0.000708 0.032744 
Zfhx2 14 zinc finger homeobox 2 -16.944 -0.87184 0.000992 0.042032 
Adcy4 14 adenylate cyclase 4 -17.3132 -0.83797 0.001045 0.04366 
Glrx5 14 glutaredoxin 5 -13.6719 0.665232 0.001106 0.045061 
Cdh24 14 cadherin 24, type 2 -15.4914 -0.64444 0.001411 0.053302 
Mir369 14 microRNA 369 -19.2576 -1.21017 0.00143 0.053815 
Mir134 14 microRNA 134 -19.1782 -1.19733 0.00155 0.057092 
Actc1 15 actin, alpha, cardiac muscle  -16.6388 -4.14917 8.04E-12 2.79E-08 
Aldh1a3 15 aldehyde dehydrogenase 1 family, member 
A3 
-19.7399 -2.15043 1.92E-06 0.000384 
Snora24 15 Small nucleolar RNA SNORA24 -14.5695 -1.59453 2.45E-06 0.000451 
Cyp11a1 15 cytochrome P450, family 11, subfamily A, 
polypeptide 1 
-19.3938 -1.95518 9.98E-06 0.001228 
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Table 4.2, continued 
Mtap1a 15 microtubule-associated protein 1A -17.3688 -1.09265 4.64E-05 0.004317 
Cspg4 15 chondroitin sulfate proteoglycan 4 -18.9071 -1.40771 5.59E-05 0.00486 
Alpk3 15 alpha-kinase 3 -18.6611 -1.20991 0.000723 0.03306 
Gatm 15 glycine amidinotransferase (L-
arginine:glycine amidinotransferase) 
-17.3979 -0.8511 0.001356 0.052672 
Snora30 16 small nucleolar RNA, H/ACA box 30 -15.027 -1.55106 1.23E-06 0.000277 
Prss22 16 protease, serine, 22 -19.5145 -1.56822 9.84E-05 0.007247 
Maf 16 v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog (avian) 
-19.4696 -1.52805 0.000101 0.007352 
Crispld2 16 cysteine-rich secretory protein LCCL 
domain containing 2 
-18.6821 -1.23494 0.000116 0.008081 
Slc6a2 16 solute carrier family 6 (neurotransmitter 
transporter, noradrenalin), member 2 
-19.4005 -1.45123 0.000223 0.013589 
Snord68 16 small nucleolar RNA, C/D box 68 -12.5653 -0.84071 0.000486 0.02506 
Cldn9 16 claudin 9 -19.9406 -1.5883 0.000493 0.02533 
Emp2 16 epithelial membrane protein 2 -18.416 -1.06638 0.000574 0.028296 
Snora21 17 Small nucleolar RNA SNORA21 -12.4768 -1.99596 3.46E-09 2.32E-06 
Col1a1 17 collagen, type I, alpha 1 -15.7799 -1.61354 1.30E-08 6.23E-06 
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Table 4.2, continued 
Unc45b 17 unc-45 homolog B (C. elegans) -18.553 -2.76615 9.93E-08 3.33E-05 
Meox1 17 mesenchyme homeobox 1 -19.0625 -1.89839 5.53E-07 0.000151 
Myocd 17 myocardin -18.5487 -2.19579 1.10E-06 0.000259 
Snord104 17 small nucleolar RNA, C/D box 104 -10.2146 -1.10626 4.23E-06 0.0007 
Myl4 17 myosin, light chain 4, alkali; atrial, 
embryonic 
-18.7853 -2.53523 6.12E-06 0.000912 
Ace 17 angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
-19.2534 -1.63179 1.08E-05 0.001304 
Krt20 17 keratin 20 -20.3096 -2.11016 1.98E-05 0.002182 
Hoxb3 17 homeobox B3 -19.8492 -1.76852 5.34E-05 0.004773 
Sdk2 17 sidekick cell adhesion molecule 2 -16.8093 -0.96234 5.57E-05 0.00486 
Dhrs11 17 dehydrogenase/reductase (SDR family) 
member 11 
-16.2865 0.912026 8.48E-05 0.006685 
Hoxb2 17 homeobox B2 -18.9097 -1.42459 0.000173 0.010975 
Lrrc48 17 leucine rich repeat containing 48 -19.7083 -1.57399 0.000182 0.011375 
Srcin1 17 SRC kinase signaling inhibitor 1 -18.2753 -1.09537 0.000246 0.014658 
Zbtb4 17 zinc finger and BTB domain containing 4 -17.716 -1.03904 0.000272 0.015788 
Slc4a1 17 solute carrier family 4, anion exchanger, -11.6811 0.698117 0.000485 0.02506 
Table 4.2, continued 
9
2
  
 
 
 
 
 
Table 4.2, continued 
member 1 (erythrocyte membrane protein 
band 3, Diego blood group) 
Pnpo 17 pyridoxamine 5'-phosphate oxidase -13.8165 0.697429 0.000658 0.030993 
Snord7 17 small nucleolar RNA, C/D box 7 -14.3611 -1.06298 0.000691 0.032155 
Snord49a 17 small nucleolar RNA, C/D box 49A -11.8254 -0.91994 0.000843 0.037314 
Smtnl2 17 smoothelin-like 2 -17.6135 -0.8729 0.000994 0.042032 
Vamp2 17 Vesicle-associated membrane protein 2 -16.4967 -0.75869 0.001111 0.045139 
Kdm6b 17 lysine (K)-specific demethylase 6B -14.488 -0.75868 0.001148 0.046356 
Shpk 17 sedoheptulokinase -20.5893 1.80572 0.001179 0.047338 
Myom1 18 myomesin 1, 185k -17.8351 -1.87926 9.89E-08 3.33E-05 
Snord58b 18 small nucleolar RNA, C/D box 58B -15.7358 -1.20173 3.21E-06 0.000566 
Klhl14 18 kelch-like 14 (Drosophila) -19.4027 -1.80878 1.63E-05 0.001856 
Gata6 18 GATA binding protein 6 -17.7275 -1.26719 4.48E-05 0.004227 
Ccbe1 18 collagen and calcium binding EGF domains 
1 
-16.9422 -0.99822 0.000174 0.011018 
Fosb 19 FBJ murine osteosarcoma viral oncogene 
homolog B 
-15.1277 1.536375 1.02E-08 5.04E-06 
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Table 4.2, continued 
Cnn1 19 calponin 1, basic, smooth muscle -19.5138 -3.20421 2.67E-08 1.12E-05 
Blvrb 19 biliverdin reductase B (flavin reductase 
(NADPH)) 
-16.3525 1.086488 3.61E-06 0.000613 
Lgi4 19 leucine-rich repeat LGI family, member 4 -19.3967 -1.81308 4.89E-06 0.000793 
Acp5 19 acid phosphatase 5, tartrate resistant -15.2369 0.965548 7.68E-06 0.001084 
Epor 19 erythropoietin receptor -16.2868 0.942723 5.24E-05 0.004713 
Klf1 19 Kruppel-like factor 1 (erythroid) -16.8095 1.088061 5.72E-05 0.00492 
Rps19 19 ribosomal protein S19 -13.1258 0.793089 9.11E-05 0.00694 
Snord111 19 Small Nucleolar RNA SNORD111 -15.2534 -0.93757 9.62E-05 0.007166 
Matk 19 megakaryocyte-associated tyrosine kinase -20.713 -2.22046 0.000104 0.007401 
Kcnn4 19 potassium intermediate/small conductance 
calcium-activated channel, subfamily N, 
member 4 
-17.362 1.011583 0.000123 0.008576 
Gdf1 19 growth differentiation factor 1 -17.7558 -0.99711 0.000144 0.009565 
Lass1 19 ceramide synthase 1 -17.7558 -0.99711 0.000144 0.009565 
Icam4 19 intercellular adhesion molecule 4 
(Landsteiner-Wiener blood group) 
-19.7537 1.630118 0.000244 0.014658 
Snord35a 19 small nucleolar RNA, C/D box 35A -10.6831 -0.924 0.000245 0.014658 
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Table 4.2, continued 
Prr12 19 proline rich 12 -14.6841 -0.85625 0.000261 0.01543 
Snord34 19 small nucleolar RNA, C/D box 34 -10.9436 -0.71732 0.000775 0.035204 
Rps28 19 ribosomal protein S28 -15.271 0.775647 0.001197 0.047899 
Zglp1 19 zinc finger, GATA-like protein 1 -19.7026 1.323064 0.001275 0.050454 
Rps11 19 ribosomal protein S11 -11.1502 0.642368 0.001276 0.050454 
Mrpl34 19 mitochondrial ribosomal protein L34 -15.4658 0.691345 0.00139 0.052806 
Snord12 20 small nucleolar RNA, C/D box 12 -14.4493 -1.31812 1.27E-06 0.00028 
Trib3 20 tribbles homolog 3 (Drosophila) -18.0105 1.463354 1.79E-06 0.000364 
Snord17 20 Small nucleolar RNA, c/d box 17 -12.9254 -1.01915 6.20E-05 0.005199 
Prokr2 20 prokineticin receptor 2 -20.7105 -2.22245 6.85E-05 0.00563 
Snord110 20 small nucleolar RNA, C/D box 110 -13.0942 -0.96188 0.000155 0.010178 
Ahcy 20 adenosylhomocysteinase -14.2912 -0.92902 0.000566 0.028209 
Myl9 20 myosin, light chain 9, regulatory -15.7858 -0.91342 0.000663 0.03109 
Snhg11 20 small nucleolar RNA host gene 11 -16.849 -0.76732 0.001536 0.056742 
Sh3bgr 21 SH3 domain binding glutamic acid-rich 
protein 
-20.2103 -4.0535 4.78E-10 4.58E-07 
Snora81 21 Small nucleolar RNA SNORA81 -14.2374 -1.44847 2.79E-05 0.002834 
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Table 4.2, continued 
Mrap 21 melanocortin 2 receptor accessory protein -18.2549 1.263949 4.80E-05 0.004436 
Ubash3a 21 ubiquitin associated and SH3 domain 
containing A 
-19.098 1.487342 0.000131 0.008989 
Col6a2 21 collagen, type VI, alpha 2 -18.5626 -1.16626 0.000254 0.015089 
Cldn8 21 claudin 8 -17.1882 -0.95183 0.000282 0.016074 
Erg 21 v-ets erythroblastosis virus E26 oncogene 
homolog (avian) 
-16.626 -0.80155 0.001238 0.049402 
Tiam1 21 T-cell lymphoma invasion and metastasis 1 -13.9473 -0.69161 0.001528 0.05657 
Myo18b 22 myosin XVIIIB -20.3054 -2.39451 7.47E-06 0.001065 
Sox10 22 SRY (sex determining region Y)-box 10 -19.4735 -1.77688 8.08E-06 0.001084 
Grap2 22 GRB2-related adaptor protein 2 -18.5699 1.342658 3.40E-05 0.003307 
Snora15 22 Small nucleolar RNA SNORA15 -15.114 -0.84291 0.0013 0.051124 
Snora31 1,2,5,7,11,17,
X 
Small nucleolar RNA SNORA31 -14.1166 -1.09201 5.06E-05 0.004582 
Snora68 5,13,17,19,X Small nucleolar RNA SNORA68 -11.463 -1.11328 5.62E-05 0.00486 
Scarna6 6,15 Small Cajal body specific RNA 6 -15.1266 -1.76637 1.21E-09 9.51E-07 
Slc38a5 X solute carrier family 38, member 5 -17.6398 1.361652 8.63E-07 0.000206 
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Table 4.2, continued 
Gata1 X GATA binding protein 1 (globin 
transcription factor 1) 
-15.8758 1.071303 1.54E-06 0.000323 
Alas2 X aminolevulinate, delta-, synthase 2 -13.0776 0.966691 8.37E-06 0.001084 
5730405O15Ri
k 
X RIKEN cDNA 5730405O15 gene -20.7408 -2.54656 1.95E-05 0.002182 
Dcx X doublecortin -18.5436 -1.20738 0.000226 0.01372 
Nrk X Nik related kinase -15.9088 -0.80339 0.000572 0.028278 
L1cam X L1 cell adhesion molecule -19.0181 -1.27982 0.000713 0.032745 
Prl7a1  prolactin family 7, subfamily a, member 1 -19.3097 -3.63051 2.62E-11 7.04E-08 
Scarna3b  small Cajal body-specific RNA 3B -16.899 -2.93309 2.24E-10 3.10E-07 
Psg29  pregnancy-specific glycoprotein 29 -20.2687 -3.50461 2.40E-10 3.10E-07 
2610203C20Rik RIKEN cDNA 2610203C20 gene -16.8671 -1.63036 2.55E-10 3.10E-07 
Mir1843  small Cajal body-specific RNA 3B -16.9266 -2.94422 4.36E-10 4.50E-07 
Mir5117  growth arrest specific 5 -12.4139 -1.88468 6.57E-10 5.87E-07 
Hbb-bh1  hemoglobin Z, beta-like embryonic chain -8.50035 1.222477 1.12E-09 9.41E-07 
C430049B03Rik RIKEN cDNA C430049B03 gene -15.8243 -1.48415 2.47E-09 1.74E-06 
Mir1843b  small Cajal body-specific RNA 3A -15.5633 -2.14558 6.34E-09 3.54E-06 
Table 4.2, continued 
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Table 4.2, continued 
Snord16a  Small nucleolar RNA SNORD16 -12.3603 -2.01119 7.51E-09 3.95E-06 
Scarna3a  small Cajal body-specific RNA 3A -15.5348 -2.13221 7.66E-09 3.95E-06 
Prl2c3  prolactin family 2, subfamily c, member 3 -19.154 -2.72545 6.08E-08 2.27E-05 
Prl2c4  prolactin family 2, subfamily c, member 3 -19.154 -2.72545 6.08E-08 2.27E-05 
Epb4.2  erythrocyte protein band 4.2 -15.2304 1.161039 7.73E-08 2.80E-05 
Rps19-ps3 ribosomal protein S19, pseudogene 3 -17.4107 1.327991 7.89E-07 0.000192 
4732471J01Rik RIKEN cDNA 4732471J01 gene -19.6669 -1.98292 2.15E-06 0.000412 
1190007F08Rik RIKEN cDNA 1190007F08 gene -15.8117 1.099543 3.39E-06 0.000583 
Mir3066  microRNA 3066 -20.3478 -2.31155 5.43E-06 0.000827 
3632451O06Rik RIKEN cDNA 3632451O06 gene -14.8471 -1.51158 8.07E-06 0.001084 
Mir666  microRNA 666 -19.1832 -1.65825 8.40E-06 0.001084 
2900060B14Rik RIKEN cDNA 2900060B14 gene -15.1019 -1.27834 8.46E-06 0.001084 
Mir3096b  misc RNA RefSeq import -16.1132 -1.41513 8.49E-06 0.001084 
Gm98  predicted gene 98 -15.5691 -0.96993 2.48E-05 0.002595 
Hist1h4n  histone cluster 1, H4n -14.3459 1.084602 2.76E-05 0.002829 
5730408K05Rik Small nucleolar RNA SNORA57 -12.166 0.940994 3.72E-05 0.003565 
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Table 4.2, continued 
Snhg8  small nucleolar RNA, H/ACA box 24 -14.1852 -1.23896 4.43E-05 0.004209 
Iigp1  interferon inducible GTPase 1 -20.695 -2.25334 4.51E-05 0.004228 
Mir3068  Small nucleolar RNA SNORA58 -16.9569 -1.54999 4.84E-05 0.004441 
Gm9855  predicted pseudogene 9855 -15.6426 0.877228 5.58E-05 0.00486 
Hba-x  hemoglobin X, alpha-like embryonic chain 
in Hba complex 
-8.92932 0.784263 8.17E-05 0.006559 
Prl3d1  prolactin family 3, subfamily d, member 1 -19.3368 -1.80992 8.43E-05 0.006684 
Hbb-y  hemoglobin Y, beta-like embryonic chain -7.70578 0.721147 8.85E-05 0.00679 
Tex16  testis expressed gene 16 -20.2618 -1.94091 9.40E-05 0.00708 
Mir667 , microRNA 667 -20.7321 -2.19009 0.000104 0.007401 
Car7  carbonic anhydrase 7 -20.2674 -1.95244 0.000126 0.008704 
Mir1931  microRNA 1931 -18.6918 -1.23285 0.000281 0.016074 
2610507I01Rik RIKEN cDNA 2610507I01 gene -17.7527 -1.03234 0.000289 0.016365 
Mir3091  microRNA 3091 -17.3273 0.927263 0.000299 0.016803 
Hbq1b  hemoglobin, theta 1B -19.1536 1.375773 0.000316 0.017375 
2010300C02Rik RIKEN cDNA 2010300C02 gene -19.2387 -1.355 0.000368 0.01996 
1700012D14Rik RNA RefSeq import -19.9594 -1.56384 0.000372 0.020116 
9
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Table 4.2, continued 
Mtrnr2l  Mtrnr2-like -14.6859 0.786393 0.00042 0.022153 
1300017J02Rik RIKEN cDNA 1300017J02 gene -17.1708 0.880019 0.000554 0.027829 
2410015M20Rik RIKEN cDNA 2410015M20 gene -15.8287 0.754478 0.000617 0.02984 
Zfp78  zinc finger protein 78 -19.4938 -1.3719 0.000619 0.02984 
Gm5177  pseudogene RefSeq import -17.5387 -0.96141 0.000633 0.030299 
AI450353  misc RNA RefSeq import -14.0505 -0.94812 0.000703 0.032631 
Cdk3-ps  cyclin-dependent kinase 3, pseudogene -20.3686 -1.74357 0.000805 0.036095 
Mir686  microRNA 686 -15.8143 0.857422 0.00083 0.03697 
5730508B09Rik RIKEN cDNA 5730508B09 gene -18.2607 1.018964 0.000949 0.041159 
H2-D1  histocompatibility 2, D region locus 1 -18.6465 -1.121 0.000968 0.041592 
Mirlet7a-1 microRNA let7a-1 -17.5976 -0.88458 0.001061 0.044025 
C78339  expressed sequence C78339 -15.3114 -0.76824 0.00137 0.052806 
2210403K04Rik RIKEN cDNA 2210403K04 gene -19.4081 -1.2185 0.001382 0.052806 
Gm6251  ribosomal protein L32 -16.5523 0.798314 0.001383 0.052806 
AF357355  snoRNA AF357355 -13.2361 -0.81269 0.00139 0.052806 
       
Genes with no listed human chromosome were genes only found in mosue.    
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Table 4.3: Number of Unique Mmu 16 Transcript Variants of Genes with 
Homologues on Hsa21 found Using Ensembl and NCBI/GenBank Databases 
Gene Ensembl NCBI/GenBank 
Dyrk1a 6 2 
Rcan1 2 2 
Tiam1 15 3 
Erg 9 1 
Sh3bgr 8 1 
Cldn8 1 1 
Mrap 4 1 
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Table 4.4: List of Mmu Genes Containing Alternative Splicing Events between 
Trisomic and Euploid E9.5 PA1 and E9.25 NT Tissue 
Comparison 1 Comparison 2 Comparison 3 Comparison 4
Euploid PA1 (E9.5) 
and Trisomic PA1 
(E9.5)
Euploid NT (E9.25) 
and Trisomic NT 
(E9.25)
Euploid PA1 (E9.5) 
and Euploid NT 
(E9.25)
Trisomic PA1 (E9.5) 
and Trisomic NT 
(E9.25)
Sumo1 Rbms3 Rpl13a Zcchc17 Snf8 Atp5l Ccnl1
Ccnl1 Gpbp1 Snord32a Uap1 Uqcrh Cttn Pex2
Rpl11 Tlk1 Brd8 Eif4a2 Tomm70a Srsf7 Acot8
Nop56 Cab39l Klhl26 Brd8 Ttc3 Rpl11 Cd59a
Ccnl1 Btrc Abl2 Uap1 Ankrd10 Pes1
Ctbp2 Ttbk2 Pex2 Mtch2 Tk2 Zmym3
Tpp2 Ccbl1 Timm9 Nop56 Apobec3 Fgfr1op2
Zmym3 Dtx2 Cdc14b Tpp2 Sipa1 Ccnl1
Fam76a Rab3il1 Top3b Bin1 Nadk2 Arl16
Tecr C330007P06RikChpf Fgfr1op2 Trub2 Fgfr2
Nbr1 Tomm22 Tmem198 Fam76a Foxk2 2810474O19Rik
Sun1 Pcmt1 Esd Hnrnpr Srr Xpnpep3
Tomm70a Ctage5 Dph3 Tmem164 Repin1 Dph3
Foxk2 Ttc3 Oxnad1 Cab39l Car2 Oxnad1
Parp11 Eif4enif1 Rhot1 Acly Pnpo Tsr3
Arl16 Mdm4 Dhfr Dph3 Timm9 Slc29a1
Klhl18 4632434I11RikMsh3 Oxnad1 Mtss1 Git2
Tex30 Fam220a C2cd5 Zfand3 Gprasp1 Mboat7
Srp19 Dlg1 Tm2d3 Slc22a17 Armcx5 Klhl26
Ankrd10 Tcof1 Xpnpep3 Hnrnpr Rdh13 Wnk1
Tmem57 Golm1 Cnot4 Meg3 Timm9 Dpm1
Blcap Zfand3 Eif4g3 Mir1906-2 Ttc13 Zfp454
Nnat Csnk1g1 Repin1 Mir1906-1 Pxdn Tmem222
Rbck1 Kif1c Ndufs1 Map2 Asap2
Ppp4r1l-ps Hnrnpa2b1Kif1c Rbck1
Ddit3 Suv39h2 Sec24b Nbr1
Lrp8 Pnpo Tlk1 Slc29a1
Cdc14b Top3b Stk19 Ccbl1  
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Figure 1.1: Nondisjunction in Meiosis I and Meiosis II causes Trisomy 21.  Trisomy 
21 in humans is caused by nondisjunction of chromosome 21 during Meiosis I or II.  (a) 
In Meiosis I when homologous chromsomes fail to separate, one daughter cell will 
contain an extra chromosome 21, while the other will lack a chromosome. After division 
of sister chromatids in Meiosis II, the resulting gametes from the first daughter cell will 
contain the extra chromosome (n+1), while the set of gametes from the second daughter 
cell will lack the chromosome (n-1). (b) When Meiosis I proceeds normally, but sister 
chromatids fail to separate during Meiosis II, the gametes from the cell with the extra 
chromatid will divide unevenly into a gamete containing an extra chromosome 21 (n+1) 
and a gamete lacking a chromosome 21 (n-1). When any (n+1) gametes are united with a 
normal gamete from another parent, the resulting zygote will contain the normal 
chromosome compliment for each chromosome except for an extra copy of chromosome 
21 (2n+1). This occurrence is referred to as Trisomy 21, referring to the three copies of 
chromosome 21 relative to the normal two copies of all other autosomal chromosomes. 
88% of cases of DS arise from nondisjunction of Hsa21 in the oocyte, rather than the 
sperm (http://www.bio.miami.edu/~cmallery/150/mendel/c15x11nondisjunction.jpg). 
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Figure 1.2: Gene Homology between Mmu16 and Hsa21.  Diagram detailing gene 
homology between the extra chromosome 16 in mouse (Mmu16) displayed in segmental 
trisomy in Ts65Dn mice and Hsa21.  The extra Mmu16 chromosome in Ts65Dn mice 
contains ~50% of the genes on Hsa21. 
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Figure 1.3: Regional Cranial Homology of the Ts65Dn and Human Skull.  Ts65Dn 
mice contain ~50% of the gene homologues found on Hsa21 and mirror many of the 
craniofacial and other phenotypes displayed in DS including the reduced size of the 
maxilla (pink) and mandible (purple), a flattened occiput (red), flattened nasal bridge 
(green), and reduced bizygomatic breadth (pink) (RICHTSMEIER et al. 2000; RICHTSMEIER 
et al. 2002; SHOTT 2006; STARBUCK et al. 2013). 
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Figure 1.4: Differentiation Potential of Neural Crest Cells in the Neural Tube. 
Neural crest cells originating from the dorsal side of the neural tube may become either 
cranial neural crest cells or trunk neural crest cells.  Cranial neural crest cells differentiate 
into the neurons and glia of the cranial ganglia, cartilage, bone, and connective tissue of 
the head, face, and neck.  Trunk neural crest cells differentiate into a variety of cell types 
including, sympahto-adrenal cells, sensory neurons and glia, and pigment cells. Cranial 
neural crest and the building of the vertebrate head  (KNECHT and BRONNER-FRASER 
2002). 
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Figure 1.5: Whole mount Ts65Dn, Wnt1lacZ/+ Euploid E9.5 Embryo with Labeled 
Neural Crest Cells. Picture of a whole E9.5 euploid embryo with neural crest cell-
derived structures labeled in blue with β-galactosidase. The developing first pharyngeal 
arch (PA1), visible just below the head (circled in red), will contribute to the bones and 
connective tissue, and musculature of the jaw and lower face (ROPER et al. 2009). 
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Figure 1.6: Developmental Homology of the Bird, Mouse, and Human Skull. The 
skull of bird, mouse, and humans show similar homologous structures which originate 
from near identical early embryonic patterns of development in the head in addition to 
migration of neural crest cells to populate the BA1, BA2, and BA3 (also known as PA1, 
PA2, and PA3 respectively) from their respective rhombomeres (SANTAGATI and RIJLI 
2003).   
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Figure 1.7: Migration Path of Neural Crest in the Formation of the First Pharyngeal 
Arch . Section of E9.5 Ts65Dn embryo showing the migration path (red arrow) of neural 
crest cells (NCC) delaminating from the neural tube to migrate to the developing first 
pharyngeal arch (PA1) in pre-mandible formation.   Ts65Dn embryos show deficits in the 
migration of NCC to the PA1, and failure of NCC to proliferate once in the PA1.  This 
leads to a smaller, hypocellular PA1 deficient in NCC which persists throughout 
development, and contributes to the undersized mandible in Ts65Dn mice (ROPER et al. 
2009). 
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Figure 1.8: PA1 Volume of Ts65Dn and Euploid E9.5 Embryos.  Trisomic Ts65Dn 
embryos have a smaller PA1 volume than euploid littermates at E9.5 (ROPER et al. 2009). 
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Figure 1.9: Overexpression of Dyrk1A Alters the Mechanism of the NFATc 
Pathway. (a) Shows the equilibrium of cytosolic and nuclear NFATc under normal 
expression of Dyrk1a. NFATc is a transcription factor that regulates many genes 
involved in development and the cell cycle. When phosphorylated, it is localized in the 
cytosol, and when not phosphorylated is localized in the nucleus where it is able to 
transcribe downstream genes. Under normal conditions, there is an equilibrium between 
nuclear and cytosolic NFATc. This equilibrium is maintained by Dyrk1a, Dscr1 (also 
named Rcan1), and Calceneurin.   Dyrk1a phosphorylates NFATc, causing its removal 
from the nucleus to the cytosol. Calceneurin dephosphorylates NFATc, relocalizing it to 
the nucleus where it is able to transcribe downstream genes. Dscr1 is an inhibitor of 
Calceneurin that indirectly prevents dephosphorylation of NFATc, keeping it localized in 
the cytosol. (b) Shows how overexpression of Dyrk1a causes removal of NFATc from the 
nucleus, lowering expression of NFATc-regulated genes.  In Trisomy 21, Dyrk1a and 
Dscr1 are overexpressed, disrupting the equilibrium between nuclear and cytosolic 
NFATc.  Overexpression of Dyrk1a causes excess phosphorylation of NFATc , causing 
higher levels of NFATc to be removed from the nucleus.  Excess Dscr1 prevents the 
cytosolic NFATc from being dephosphorylated, keeping it localized in the cytosol. With 
higher levels of cytosolic NFATc and lowered levels of nuclear NFATc, transcription is 
hindered, lowering expression of downstream target genes.  It is hypothesized that this 
downregulation of NFATc target genes may be a mechanism whereby overexpression of 
Dyrk1a causes dysregulation of specific genes leading to an altered phenotype in DS 
(ARRON et al. 2006). 
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Figure 1.10: Downstream Targets of the DYRK1A Protein.  Through particular 
downstream targets, including those listed above, DYRK1A plays an role important role 
in regulating development, the cell cycle, signaling, and protein synthesis.  Changes in 
the expression of DYRK1A could potentially alter these functions and lead to altered 
phenotypes (WISEMAN et al. 2009). 
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Figure 1.11: Molecular Structure of Epigallo-catechin-(3’)-gallate (EGCG). EGCG is 
a green tea polyphenol and a known small molecule inhibitor of the DYRK1A protein 
(WANG et al. 2012).  EGCG has been tested as a clinically translatable way to normalize 
DYRK1A overexpression and correct phenotypes associated with DS (BAIN et al. 2003).  
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Figure 3.1: In vitro Proliferation Assay of E9.5 PA1 and NT cells Show a Dose-
Dependent Response to EGCG. In a proliferation assay, PA1 and NT cells extracted 
from E9.5 euploid and Ts65Dn embryos were plated and grown in cell culture. Cells 
were treated with 10µM, 25µM, or 100µM of EGCG or given no treatment.  Both PA1 
and NT cells showed increases in proliferation which increase with EGCG concentration. 
These results suggest that EGCG is able to promote proliferation in vitro, providing 
evidence for the ability of EGCG to promote proliferation for in vitro studies (Deitz, 
Unpublished data).  
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Figure 3.2: Number of Neural Crest Cells in the E9.5 PA1 of G7-G8 Treated 
Embryos. The NCC number of E9.5 embryos (staged 21-24 somites; Wnt1-LacZ euploid 
fathers) whose mothers were treated with EGCG or PBS as control from G7-G8.  
Trisomic embryos treated with EGCG show a significant increase in the number of NCC 
compared to untreated trisomic embryos (**p=0.0029).  Euploid embryos treated with 
EGCG also show increased number of NCC compared to untreated euploid embryos 
(*p=0.017) indicating observed EGCG-dependent increases in NCC may not be genotype 
specific.  Ts/(Ts): trisomic embryo from trisomic mother, Eu/(Ts): euploid embryo from 
trisomic mother. 
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Figure 3.3: PA1 Volume of E9.5 PA1 of G7-G8 Treated Embryos. The PA1 volume 
of E9.5 embryos (staged 21-24 somites; Wnt1-LacZ euploid fathers) whose mothers were 
treated with EGCG or PBS as a control from G7-G8. Trisomic embryos treated with 
EGCG show a significant increase in PA1 volume compared to untreated embryos 
(***p=0.0009).  There was also a significant difference between treated and untreated 
euploid embryos (*p=0.022) suggesting that the effects of EGCG may not be genotype 
specific. Ts/(Ts): trisomic embryo from trisomic mother, Eu/(Ts): euploid embryo from 
trisomic mother. 
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Figure 3.4: Embryo Volume of E9.5 PA1 of G7-G8 Treated Embryos. The total 
embryo volume of E9.5 embryos (staged 21-24 somites; Wnt1-LacZ euploid fathers) 
whose mothers were treated with EGCG of PBS as control from G7-G8. This EGCG 
treatment did not significantly increase the embryo volume of trisomic (p=0.14) or 
euploid embryos (p=0.092). Ts/(Ts): trisomic embryo from trisomic mother, Eu/(Ts): 
euploid embryo from trisomic mother. 
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Figure 3.5: Average Total Volume Treatment Consumed by Mothers G0-G9.5.  
Ts65Dn (trisomic) or euploid mouse mothers (B6C3F1 euploid fathers) suspected to be 
pregnant after breeding were treated ad libitum with either H2O or EGCG dissolved in 
H2O from G0-G9.5. Volume of treatment consumed was measured every other day and 
recorded. There were no significant differences (p≤0.05) in the total volume of treatment 
consumed between pregnant or non-pregnant mice, trisomic or euploid mice, or between 
treatment groups.  
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Figure 3.6: Average Dosage of EGCG Administered to Mothers Treated from G0 – 
G9.5. Ts65Dn (trisomic) or euploid mouse mothers (B6C3F1 euploid fathers) suspected 
to be pregnant after breeding were treated ad libitum with either H2O or EGCG dissolved 
in H2O from G0-G9.5. Volume of treatment consumed was measured every other day, 
recorded, and intake dose of EGCG calculated for each mouse. There were no significant 
differences between doses of EGCG for any test group. Average dose of EGCG for all 
three groups was ~12.238 ± 0.732 mg EGCG/kg body weight/day (mg/kg/day).  
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Figure 3.7: Number of Neural Crest Cells in the PA1 of G0-G9.5 Treated E9.5 
Embryos. The NCC number of E9.5 embryos (staged 21-24 somites; B6C3F1 euploid 
fathers) whose mothers were treated with EGCG or water from G0-G9.5.  EGCG 
treatment from G0-G9.5 at ~12.2 mg/kg/day did not significantly alter the number of 
NCC in E9.5 euploid embryos compared to untreated embryos. The slight but non-
significant decrease in NCC in EGCG-treated Ts/(Ts) embryos was likely due to a lower 
average somite number in this group compared to water treated embryos (p=0.0613). 
Ts/(Ts): trisomic embryo from trisomic mother, Eu/(Ts): euploid embryo from trisomic 
mother, Eu/(Eu): euploid embryo from euploid mother. 
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Figure 3.8: PA1 Volume of G0-G9.5 Treated E9.5 Embryos. The PA1 volume of E9.5 
embryos (staged 21-24 somites; B6C3F1 euploid fathers) whose mothers were treated 
with EGCG or water from G0-G9.5.  No significant differences in PA1 volume were 
attributed to G0-G9.5 EGCG treatment (p=0.058). PA1 volume was significantly 
increased in EGCG-treated Eu/(Ts) embryos compared to untreated embryos (*p=0.046).  
Ts/(Ts): trisomic embryo from trisomic mother, Eu/(Ts): euploid embryo from trisomic 
mother, Eu/(Eu): euploid embryo from euploid mother. 
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Figure 3.9: Embryo Volume of G0-G9.5 Treated E9.5 Embryos. The total embryo 
volume of E9.5 embryos (staged 21-24 somites; B6C3F1 euploid fathers) whose mothers 
were treated with EGCG or water from G0-G9.5. There were no differences between 
treated and untreated embryo volume of any trisomic or euploid embryos.  Eu/(Ts) 
embryos treated with EGCG had slightly but not significantly larger embryo volume than 
embryos of all other treatment groups (p=0.089).  Ts/(Ts): trisomic embryo from trisomic 
mother, Eu/(Ts): euploid embryo from trisomic mother, Eu/(Eu): euploid embryo from 
euploid mother. 
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Figure 3.10: E9.5 Embryos from Trisomic Mothers Treated with G0-G9.5 EGCG 
Display Decreased Somite Numbers.  Ts/(Ts) and Eu/(Ts) embryos from both Wnt1-
LacZ and B6C3F1 fathers treated with EGCG G0-G9.5 displayed lower somite numbers 
on average compared to untreated embryos of the same genotype and Eu/(Eu) embryos in 
the same treatment group. This effect was more pronounced in embryos with Wnt1-LacZ 
fathers (average ~19 somites) than in embryos with B6C3F1 fathers (average ~21.5-22.5 
somites).  No significant differences were observed in somite numbers of embryos treated 
with PBS or EGCG from G7-G8. Ts/(Ts): trisomic embryos from trisomic mothers, 
Eu/(Ts): euploid embryos from trisomic mothers, Eu/(Eu): euploid embryos from euploid 
mothers). (*p≤0.05, **p≤0.01, ***p≤0.001). 
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Figure 3.11: Number of Neural Crest Cells in PA1 of G0-G9.5 Treated 18-20 Somite 
Embryos. The NCC number of E9.5 embryos with Wnt1-LacZ fathers whose trisomic 
mothers were treated with EGCG from G0-G9.5.  There are no differences in NCC 
number between trisomic and euploid embryos at this time point. These findings suggest 
that the NCC deficits in the PA1 in trisomic embryos occur after, but not during the 18-
20 somite stage. Ts/(Ts): trisomic embryos from trisomic mothers, Eu/(Ts): euploid 
embryos from trisomic mothers. 
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Figure 3.12: PA1 Volume of G0-G9.5 Treated 18-20 Somite Embryos. The PA1 
volume of E9.5 embryos with Wnt1-LacZ fathers whose trisomic mothers were treated 
with EGCG from G0-G9.5. There are no differences in PA1 volume between trisomic 
and euploid embryos at this time point. These findings provide further evidence that the 
deficits in PA1 volume in trisomic embryos likely occur after, but not during the 18-20 
somite stage. Ts/(Ts): trisomic embryos from trisomic mothers, Eu/(Ts): euploid embryos 
from trisomic mothers. 
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Figure 3.13: Embryo Volume of G0-G9.5 Treated 18-20 Somite Embryos. The 
embryo volume of E9.5 embryos with Wnt1-LacZ fathers whose trisomic mothers were 
treated with EGCG from G0-G9.5. There are no differences in total embryo volume 
between trisomic and euploid embryos at this time point. This suggests that trisomic 
embryos reach a statistically significant deficit in embryo volume compared to euploid 
littermates after, but not during the 18-20 somite stage. Ts/(Ts): trisomic embryos from 
trisomic mothers, Eu/(Ts): euploid embryos from trisomic mothers. 
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Figure 4.1: Comparison of Dyrk1a Transcript Variants from the Ensembl Genome 
Database.  Screenshot from the Ensembl Genome Database of 5 aligned protein-coding 
and 1 non-protein coding transcript variant of the Dyrk1a gene on Mmu 16. 
(http://ueast.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG000000
22897;r=16:94570010-94695517). Last accessed October 15, 2014 
 
 
 
Figure 4.2: Comparison of Rcan1 Transcript Variants from the Ensembl Genome 
Database.  Screenshot from the Ensembl Genome Database of 2 aligned protein-coding 
transcript variants of the Rcan1 gene on Mmu 16 
(http://ueast.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG000000
22951;r=16:92391953-92466146). Last accessed October 15, 2014 
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Figure 4.3: Detection of Alternative Splicing Events in Euploid and Trisomic E9.25 
Neural Tube and E9.5 PA1 Tissue. Diagram shows the number of alternative splicing 
events detected using MISO when comparing RNA sequence data from either euploid 
(Eu) or trisomic/Ts65Dn (Ts) E9.5 first pharyngeal arch (PA1) or E9.25 neural tube (NT) 
tissue.  Genes with alternative splicing events detected in multiple comparisons are 
numbered in the overlap of the yellow and blue circles and listed below. Data show 
approximately twice the number of alternative splicing events in PA1 tissue compared to 
NT tissue and in euploid NT and PA1 compared to trisomic NT and PA1. This shows that 
more alternative splicing is occurring in euploid tissues and in E9.5 PA1 tissue 
suggesting trisomy may decrease the number of alternative splicing events. This provides 
a further mechanism whereby trisomy may lead to an altered phenotype. 
  
129 
 
 
 
 
 
 
Figure 5.1: Relative Trisomic to Euploid Gene Expression in E9.5 PA1 with EGCG 
Treatment. Pregnant Ts65Dn mothers were treated with PBS or 400mg/kg/day EGCG 
twice per day on G7 and G8. Embryos were removed at G9.5 and PA1 tissue collected 
from embryos. qPCR was performed on RNA isolated taken from the E9.5 PA1 tissue.  
Expression levels of common developmental genes with a known role in DS were 
quantified.   Gene expression of Rcan1 and Shh was lower in EGCG treated samples 
compared to untreated samples. Expression of Gli1, Ptch1, and Ets2 was elevated in 
EGCG treated samples compared to untreated samples (Unpublished data, Roper). 
